<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038907</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-107</org_study_id>
    <secondary_id>2013-001419-64</secondary_id>
    <secondary_id>U1111-1147-3239</secondary_id>
    <nct_id>NCT02038907</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine</brief_title>
  <acronym>NOR-107</acronym>
  <official_title>A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted With or Without Monophosphoryl Lipid A and Aluminum Hydroxide in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to select the optimal formulation of the norovirus vaccine from
      different concentrations of virus-like particles (VLP), Aluminum Hydroxide and MPL adjuvant
      (3-O-desacyl-4'-monophosphoryl lipid A) for further development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like
      particle (VLP) vaccine adjuvanted with aluminum hydroxide and with or without monophosphoryl
      lipid A (MPL). The norovirus vaccine is being tested to assess different formulations of the
      vaccine that will then be further developed.

      This study will look at the number of antibodies to norovirus formed in people who take
      different formulations of the norovirus vaccine. The study will enroll approximately 420
      patients. Participants will be randomly assigned (by chance) to one of fourteen treatment
      groupsâ€”which will remain undisclosed to the patient and study doctor during the study (unless
      there is an urgent medical need).

      All participants will receive a vaccination on Day 1 and Day 28 of the study. Some treatment
      arms will receive one dose of the norovirus vaccine and some arms will receive two. In order
      to keep the treatment arms undisclosed to the patient and the doctor, those randomized to the
      one dose groups will receive a dose of Hepatitis A vaccine on Day 1 followed by the norovirus
      vaccine 28 days later. Participants will be asked to record any symptoms that may be related
      to the vaccine or the injection site in a diary card for 7 days after each vaccination.

      This multi-centre trial will be conducted in Belgium. The overall time to participate in this
      study is up to 393 days. Participants will make 6 visits to the clinic, and will be contacted
      by telephone twice for follow-up assessments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2014</start_date>
  <completion_date type="Actual">June 19, 2015</completion_date>
  <primary_completion_date type="Actual">June 19, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Seroresponse (Pan-Ig ELISA)</measure>
    <time_frame>Baseline and Day 56</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1</measure>
    <time_frame>Days 1 through 7</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 2</measure>
    <time_frame>Days 28 through 34</time_frame>
    <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1</measure>
    <time_frame>Days 1 through 7</time_frame>
    <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 2</measure>
    <time_frame>Days 28 through 34</time_frame>
    <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Body Temperature Within 7 Days After Dose 1</measure>
    <time_frame>Days 1 through 7</time_frame>
    <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Body Temperature Within 7 Days After Dose 2</measure>
    <time_frame>Days 28 through 34</time_frame>
    <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 up to Day 56</time_frame>
    <description>Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to Day 393</time_frame>
    <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA)</measure>
    <time_frame>Baseline and Days 28, 208 and 393</time_frame>
    <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in GI.1 VLP Antibody Titer (Pan-Ig ELISA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater from in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise from or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
    <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Baseline (Day 1) and Days 28, 56, 208 and 393</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>GMFR of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</measure>
    <time_frame>Days 28, 56, 208 and 393</time_frame>
    <description>GMFR of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Antibody Titers of Strains Not Represented in the Investigational Vaccine: Cross-Protection Assays</measure>
    <time_frame>Day 56</time_frame>
    <description>GMFR of anti-norovirus Cross-Protection Assays: GII.2 EC50, GI.3 EC50 and GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
    <description>Blocking Titers 50 (BT50) of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.2 EC50 (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Day 56</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.2 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GI.3 EC50 (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Day 56</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GI.3 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.4.2012 EC50 (HBGA)</measure>
    <time_frame>Day 1 (Baseline) and Day 56</time_frame>
    <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Significant New Medical Conditions</measure>
    <time_frame>Day 1 up to Day 56</time_frame>
    <description>Significant new medical conditions will be evaluated by the investigator for the co-existence of any of the following conditions: Adverse events of special interest (AESIs) are predefined events for potential immune mediated disorders. All AESIs are medically evaluated to assess if they might indicate an immune-mediated disorder.
Immune mediated events (IMEs) are AEs that represent a new diagnosis of a chronic medical condition that was not present or suspected prior to enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</measure>
    <time_frame>Day 1 up to Day 56</time_frame>
    <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participants is unwilling to continue because of the AE.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Norovirus, Prevention</condition>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (50/50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (50/150)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50) - Al(OH)3 (167)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50) x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (50/150) x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis A Vaccine</intervention_name>
    <description>Hepatitis A Vaccine IM injection</description>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/150)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - Al(OH)3 (167)</arm_group_label>
    <other_name>Havrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Norovirus Bivalent VLP Vaccine</intervention_name>
    <description>Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection</description>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/15) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50) - MPL (15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/15)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/50)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/150)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - Al(OH)3 (167)</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) x2</arm_group_label>
    <arm_group_label>GI.1/GII.4 (50/150) x2</arm_group_label>
    <arm_group_label>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female participants between 18 and 64 years of age at the time of enrollment.

          2. In good health at the time of entry into the trial as determined by medical history,
             physical examination (including vital signs), and clinical judgment of the
             investigator.

          3. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any trial procedures, after the
             nature of the trial has been explained according to local regulatory requirements.

          4. Can comply with trial procedures and are available for the duration of the trial.

        Exclusion Criteria:

          1. Has received any vaccines containing Hepatitis A vaccine within the past 5 years.

          2. Has contraindications, warnings, and/or precautions to vaccination with Havrix as
             specified within the Summary of Product Characteristics.

          3. Has a clinically significant active infection (as assessed by the investigator) or
             oral body temperature 38Â°C (100.4Â°F) or higher within 3 days of the intended date of
             vaccination.

          4. Has received antipyretic/analgesic medications within 24 hours prior to the intended
             vaccine administration.

          5. Known hypersensitivity or allergy to investigational vaccine (including excipients of
             the investigational vaccine).

          6. Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of
             the investigator, may interfere with the participant's ability to participate in the
             trial.

          7. Has a history of any progressive or severe neurologic disorder, seizure disorder, or
             Guillain-BarrÃ© syndrome.

          8. Has history of any illness that, in the opinion of the investigator, might interfere
             with the results of the trial or pose additional risk to the participants due to
             participation in the trial.

          9. Known or inspected impairment/alteration of immune function, including the following:

               1. Chronic use of oral steroids (Equivalent to 20 mg/day prednisone for â‰¥12 weeks/â‰¥2
                  mg/kg body weight/day for â‰¥2 weeks) within 60 days prior to Day 1 (use of
                  inhaled, intranasal, or topical corticosteroids is allowed).

               2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone â‰¥12 weeks/â‰¥2
                  mg/kg body weight/day for â‰¥2 weeks) within 60 days prior to Day 1.

               3. Receipt of immunostimulants within 60 days prior to Day 1.

               4. Receipt of parenteral, epidural, or intra-articular immunoglobulin preparation,
                  blood products, and/or plasma derivatives within 3 months prior to Day 1 or
                  planned during the full length of the trial.

               5. Receipt of immunosuppressive therapy within 6 months prior to Day 1.

               6. Human immunodeficiency virus (HIV) infection or HIV-related disease.

               7. Heritable immunodeficiency.

         10. Abnormalities of splenic or thymic function.

         11. Has a known bleeding diathesis or any condition that may be associated with a
             prolonged bleeding time.

         12. Has any serious chronic or progressive disease according to judgment of the
             investigator (eg, neoplasm, insulin dependent diabetes, cardiac, renal, or hepatic
             disease).

         13. Has a body mass index (BMI) greater than or equal to 35 kg/m^2 (=weight in kg/[height
             in meters * height in meters]).

         14. Is participating in any clinical trial with another investigational product 30 days
             prior to first trial visit or intent to participate in another clinical trial at any
             time during the conduct of this trial.

         15. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days
             (for live vaccines) prior to enrollment in this trial or who are planning to receive
             any vaccine within 28 days of investigational vaccine administration.

         16. Is first degree relatives of individuals involved in trial conduct.

         17. Has history of substance or alcohol abuse within the past 2 years.

         18. If female, of childbearing potential, sexually active, and has not used any of the
             acceptable contraceptive methods for at least 2 months prior to trial entry.

         19. Female participants of childbearing potential and sexually active, who refuse to use
             an acceptable contraceptive method from Day 1 through 6 months after the last dose of
             investigational vaccine.

         20. Female participants who plan to donate ova from Day 1 through 6 months after the last
             dose of investigational vaccine.

         21. Female participants with any positive pregnancy test.

         22. Female participants who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universiteit Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <results_first_submitted>June 18, 2016</results_first_submitted>
  <results_first_submitted_qc>June 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 1, 2016</results_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norovirus, vaccination</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
    <mesh_term>Monophosphoryl lipid A</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 2 investigative sites in Belgium from 28 March 2014 (first participants signed the informed consent form) to 19 June 2015.</recruitment_details>
      <pre_assignment_details>Healthy volunteers were enrolled equally in 1 of 14 unique formulation treatment groups: 11 formulation arms received 1 dose and 3 formulation arms received 2 doses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GI.1/GII.4 (15/15) - MPL (50)</title>
          <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
        </group>
        <group group_id="P2">
          <title>GI.1/GII.4 (15/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P3">
          <title>GI.1/GII.4 (50/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P4">
          <title>GI.1/GII.4 (15/15) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P5">
          <title>GI.1/GII.4 (15/50) - MPL (15)</title>
          <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
        </group>
        <group group_id="P6">
          <title>GI.1/GII.4 (50/50) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P7">
          <title>GI.1/GII.4 (15/15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P8">
          <title>GI.1/GII.4 (15/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P9">
          <title>GI.1/GII.4 (50/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P10">
          <title>GI.1/GII.4 (50/150)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P11">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="P12">
          <title>GI.1/GII.4 (15/50) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="P13">
          <title>GI.1/GII.4 (50/150) x2</title>
          <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="P14">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="32"/>
                <participants group_id="P9" count="29"/>
                <participants group_id="P10" count="30"/>
                <participants group_id="P11" count="29"/>
                <participants group_id="P12" count="28"/>
                <participants group_id="P13" count="29"/>
                <participants group_id="P14" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="32"/>
                <participants group_id="P9" count="29"/>
                <participants group_id="P10" count="30"/>
                <participants group_id="P11" count="27"/>
                <participants group_id="P12" count="28"/>
                <participants group_id="P13" count="29"/>
                <participants group_id="P14" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>GI.1/GII.4 (15/15) - MPL (50)</title>
          <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
        </group>
        <group group_id="B2">
          <title>GI.1/GII.4 (15/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B3">
          <title>GI.1/GII.4 (50/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B4">
          <title>GI.1/GII.4 (15/15) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B5">
          <title>GI.1/GII.4 (15/50) - MPL (15)</title>
          <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
        </group>
        <group group_id="B6">
          <title>GI.1/GII.4 (50/50) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B7">
          <title>GI.1/GII.4 (15/15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B8">
          <title>GI.1/GII.4 (15/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B9">
          <title>GI.1/GII.4 (50/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B10">
          <title>GI.1/GII.4 (50/150)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B11">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="B12">
          <title>GI.1/GII.4 (15/50) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="B13">
          <title>GI.1/GII.4 (50/150) x2</title>
          <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="B14">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="30"/>
            <count group_id="B6" value="31"/>
            <count group_id="B7" value="30"/>
            <count group_id="B8" value="32"/>
            <count group_id="B9" value="29"/>
            <count group_id="B10" value="30"/>
            <count group_id="B11" value="29"/>
            <count group_id="B12" value="28"/>
            <count group_id="B13" value="29"/>
            <count group_id="B14" value="31"/>
            <count group_id="B15" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="14.70" lower_limit="19" upper_limit="63"/>
                    <measurement group_id="B2" value="51.0" spread="14.36" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="B3" value="50.0" spread="12.95" lower_limit="22" upper_limit="64"/>
                    <measurement group_id="B4" value="50.0" spread="14.95" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="B5" value="49.5" spread="13.79" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="B6" value="50.0" spread="14.39" lower_limit="20" upper_limit="64"/>
                    <measurement group_id="B7" value="49.5" spread="14.19" lower_limit="18" upper_limit="64"/>
                    <measurement group_id="B8" value="48.5" spread="14.13" lower_limit="18" upper_limit="63"/>
                    <measurement group_id="B9" value="41.0" spread="14.82" lower_limit="21" upper_limit="63"/>
                    <measurement group_id="B10" value="51.0" spread="15.26" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B11" value="49.0" spread="15.41" lower_limit="21" upper_limit="62"/>
                    <measurement group_id="B12" value="48.5" spread="14.05" lower_limit="23" upper_limit="64"/>
                    <measurement group_id="B13" value="48.0" spread="15.06" lower_limit="22" upper_limit="63"/>
                    <measurement group_id="B14" value="44.0" spread="16.11" lower_limit="19" upper_limit="64"/>
                    <measurement group_id="B15" value="49.5" lower_limit="18" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-49 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="15"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="15"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-64 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="14"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="16"/>
                    <measurement group_id="B12" value="16"/>
                    <measurement group_id="B13" value="20"/>
                    <measurement group_id="B14" value="18"/>
                    <measurement group_id="B15" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="12"/>
                    <measurement group_id="B13" value="9"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="29"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="28"/>
                    <measurement group_id="B13" value="29"/>
                    <measurement group_id="B14" value="31"/>
                    <measurement group_id="B15" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="32"/>
                    <measurement group_id="B9" value="29"/>
                    <measurement group_id="B10" value="30"/>
                    <measurement group_id="B11" value="29"/>
                    <measurement group_id="B12" value="28"/>
                    <measurement group_id="B13" value="29"/>
                    <measurement group_id="B14" value="31"/>
                    <measurement group_id="B15" value="420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.0" lower_limit="156" upper_limit="187"/>
                    <measurement group_id="B2" value="167.0" lower_limit="154" upper_limit="193"/>
                    <measurement group_id="B3" value="166.5" lower_limit="153" upper_limit="191"/>
                    <measurement group_id="B4" value="167.0" lower_limit="149" upper_limit="187"/>
                    <measurement group_id="B5" value="171.0" lower_limit="155" upper_limit="186"/>
                    <measurement group_id="B6" value="169.0" lower_limit="153" upper_limit="190"/>
                    <measurement group_id="B7" value="173.5" lower_limit="154" upper_limit="189"/>
                    <measurement group_id="B8" value="169.5" lower_limit="161" upper_limit="192"/>
                    <measurement group_id="B9" value="171.0" lower_limit="153" upper_limit="193"/>
                    <measurement group_id="B10" value="167.0" lower_limit="153" upper_limit="186"/>
                    <measurement group_id="B11" value="172.0" lower_limit="156" upper_limit="199"/>
                    <measurement group_id="B12" value="171.5" lower_limit="161" upper_limit="192"/>
                    <measurement group_id="B13" value="170.0" lower_limit="153" upper_limit="187"/>
                    <measurement group_id="B14" value="175.0" lower_limit="146" upper_limit="192"/>
                    <measurement group_id="B15" value="170.0" lower_limit="146" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.50" lower_limit="49.4" upper_limit="105.2"/>
                    <measurement group_id="B2" value="65.60" lower_limit="49.1" upper_limit="103.0"/>
                    <measurement group_id="B3" value="70.60" lower_limit="50.8" upper_limit="104.0"/>
                    <measurement group_id="B4" value="66.60" lower_limit="42.2" upper_limit="103.3"/>
                    <measurement group_id="B5" value="71.60" lower_limit="47.6" upper_limit="101.9"/>
                    <measurement group_id="B6" value="68.50" lower_limit="44.0" upper_limit="96.0"/>
                    <measurement group_id="B7" value="72.50" lower_limit="45.8" upper_limit="104.5"/>
                    <measurement group_id="B8" value="74.35" lower_limit="52.0" upper_limit="110.3"/>
                    <measurement group_id="B9" value="76.00" lower_limit="54.8" upper_limit="101.2"/>
                    <measurement group_id="B10" value="69.85" lower_limit="50.5" upper_limit="92.6"/>
                    <measurement group_id="B11" value="70.00" lower_limit="49.6" upper_limit="94.0"/>
                    <measurement group_id="B12" value="75.50" lower_limit="42.5" upper_limit="92.5"/>
                    <measurement group_id="B13" value="70.60" lower_limit="49.2" upper_limit="111.8"/>
                    <measurement group_id="B14" value="69.90" lower_limit="51.0" upper_limit="111.3"/>
                    <measurement group_id="B15" value="70.8" lower_limit="42.2" upper_limit="111.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.22" lower_limit="16.7" upper_limit="33.6"/>
                    <measurement group_id="B2" value="23.97" lower_limit="18.9" upper_limit="34.2"/>
                    <measurement group_id="B3" value="26.11" lower_limit="17.3" upper_limit="33.4"/>
                    <measurement group_id="B4" value="23.62" lower_limit="18.7" upper_limit="33.7"/>
                    <measurement group_id="B5" value="24.51" lower_limit="18.6" upper_limit="34.2"/>
                    <measurement group_id="B6" value="24.73" lower_limit="17.6" upper_limit="34.4"/>
                    <measurement group_id="B7" value="24.40" lower_limit="18.1" upper_limit="33.7"/>
                    <measurement group_id="B8" value="24.06" lower_limit="17.8" upper_limit="33.2"/>
                    <measurement group_id="B9" value="26.06" lower_limit="19.0" upper_limit="34.6"/>
                    <measurement group_id="B10" value="25.02" lower_limit="20.0" upper_limit="34.4"/>
                    <measurement group_id="B11" value="23.66" lower_limit="18.1" upper_limit="32.3"/>
                    <measurement group_id="B12" value="24.24" lower_limit="14.9" upper_limit="32.7"/>
                    <measurement group_id="B13" value="23.19" lower_limit="18.7" upper_limit="33.8"/>
                    <measurement group_id="B14" value="24.54" lower_limit="17.9" upper_limit="33.5"/>
                    <measurement group_id="B15" value="24.52" lower_limit="14.9" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA)</title>
        <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
        <time_frame>Baseline and Day 56</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse (Pan-Ig ELISA)</title>
          <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="26"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                    <measurement group_id="O2" value="62.1" lower_limit="42.3" upper_limit="79.3"/>
                    <measurement group_id="O3" value="46.4" lower_limit="27.5" upper_limit="66.1"/>
                    <measurement group_id="O4" value="35.5" lower_limit="19.2" upper_limit="54.6"/>
                    <measurement group_id="O5" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                    <measurement group_id="O6" value="67.7" lower_limit="48.6" upper_limit="83.3"/>
                    <measurement group_id="O7" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O8" value="62.5" lower_limit="43.7" upper_limit="78.9"/>
                    <measurement group_id="O9" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                    <measurement group_id="O10" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O11" value="46.2" lower_limit="26.6" upper_limit="66.6"/>
                    <measurement group_id="O12" value="71.4" lower_limit="51.3" upper_limit="86.8"/>
                    <measurement group_id="O13" value="69.0" lower_limit="49.2" upper_limit="84.7"/>
                    <measurement group_id="O14" value="56.7" lower_limit="37.4" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
        <time_frame>Days 1 through 7</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 1</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="32.3"/>
                    <measurement group_id="O5" value="46.7"/>
                    <measurement group_id="O6" value="38.7"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="53.1"/>
                    <measurement group_id="O9" value="44.8"/>
                    <measurement group_id="O10" value="53.3"/>
                    <measurement group_id="O11" value="48.3"/>
                    <measurement group_id="O12" value="46.4"/>
                    <measurement group_id="O13" value="31.0"/>
                    <measurement group_id="O14" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3.4"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 2</title>
        <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
        <time_frame>Days 28 through 34</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Dose 2</title>
          <description>Solicited local AEs at injection site are defined as: pain, erythema, induration, and swelling that occurred within 7 days after each vaccination.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="51.6"/>
                    <measurement group_id="O5" value="53.3"/>
                    <measurement group_id="O6" value="58.1"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="43.8"/>
                    <measurement group_id="O9" value="48.3"/>
                    <measurement group_id="O10" value="46.7"/>
                    <measurement group_id="O11" value="34.5"/>
                    <measurement group_id="O12" value="32.1"/>
                    <measurement group_id="O13" value="41.4"/>
                    <measurement group_id="O14" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3.4"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="3.4"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3.2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="6.9"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1</title>
        <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
        <time_frame>Days 1 through 7</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 1</title>
          <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="26.7"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="19.4"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="12.9"/>
                    <measurement group_id="O7" value="13.3"/>
                    <measurement group_id="O8" value="25.0"/>
                    <measurement group_id="O9" value="27.6"/>
                    <measurement group_id="O10" value="20.0"/>
                    <measurement group_id="O11" value="13.8"/>
                    <measurement group_id="O12" value="17.9"/>
                    <measurement group_id="O13" value="31.0"/>
                    <measurement group_id="O14" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="19.4"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="12.9"/>
                    <measurement group_id="O7" value="13.3"/>
                    <measurement group_id="O8" value="15.6"/>
                    <measurement group_id="O9" value="17.2"/>
                    <measurement group_id="O10" value="20.0"/>
                    <measurement group_id="O11" value="24.1"/>
                    <measurement group_id="O12" value="25.0"/>
                    <measurement group_id="O13" value="17.2"/>
                    <measurement group_id="O14" value="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="6.7"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="9.7"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="18.8"/>
                    <measurement group_id="O9" value="10.3"/>
                    <measurement group_id="O10" value="10.0"/>
                    <measurement group_id="O11" value="17.2"/>
                    <measurement group_id="O12" value="10.7"/>
                    <measurement group_id="O13" value="3.4"/>
                    <measurement group_id="O14" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="6.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="3.3"/>
                    <measurement group_id="O8" value="6.3"/>
                    <measurement group_id="O9" value="6.9"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="3.6"/>
                    <measurement group_id="O13" value="3.4"/>
                    <measurement group_id="O14" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3.2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="16.1"/>
                    <measurement group_id="O5" value="20.0"/>
                    <measurement group_id="O6" value="6.5"/>
                    <measurement group_id="O7" value="13.3"/>
                    <measurement group_id="O8" value="12.5"/>
                    <measurement group_id="O9" value="13.8"/>
                    <measurement group_id="O10" value="10.0"/>
                    <measurement group_id="O11" value="6.9"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="10.3"/>
                    <measurement group_id="O14" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 2</title>
        <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
        <time_frame>Days 28 through 34</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Dose 2</title>
          <description>Solicited systemic AEs are defined as: headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea that occurred within 7 days after each vaccination.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="22.6"/>
                    <measurement group_id="O5" value="23.3"/>
                    <measurement group_id="O6" value="16.1"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="21.9"/>
                    <measurement group_id="O9" value="20.7"/>
                    <measurement group_id="O10" value="10.0"/>
                    <measurement group_id="O11" value="13.8"/>
                    <measurement group_id="O12" value="14.3"/>
                    <measurement group_id="O13" value="34.5"/>
                    <measurement group_id="O14" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="13.3"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="12.9"/>
                    <measurement group_id="O5" value="10.0"/>
                    <measurement group_id="O6" value="12.9"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="18.8"/>
                    <measurement group_id="O9" value="17.2"/>
                    <measurement group_id="O10" value="13.3"/>
                    <measurement group_id="O11" value="13.8"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="13.8"/>
                    <measurement group_id="O14" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="13.3"/>
                    <measurement group_id="O6" value="12.9"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6.3"/>
                    <measurement group_id="O9" value="6.9"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="10.3"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="3.2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3.1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="3.6"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="12.9"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="9.7"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="15.6"/>
                    <measurement group_id="O9" value="17.2"/>
                    <measurement group_id="O10" value="10.0"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="6.9"/>
                    <measurement group_id="O14" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Body Temperature Within 7 Days After Dose 1</title>
        <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
        <time_frame>Days 1 through 7</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Body Temperature Within 7 Days After Dose 1</title>
          <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" spread="0.294"/>
                    <measurement group_id="O2" value="36.76" spread="0.376"/>
                    <measurement group_id="O3" value="36.66" spread="0.345"/>
                    <measurement group_id="O4" value="36.71" spread="0.260"/>
                    <measurement group_id="O5" value="36.65" spread="0.388"/>
                    <measurement group_id="O6" value="36.67" spread="0.255"/>
                    <measurement group_id="O7" value="36.74" spread="0.323"/>
                    <measurement group_id="O8" value="36.63" spread="0.366"/>
                    <measurement group_id="O9" value="36.52" spread="0.405"/>
                    <measurement group_id="O10" value="36.77" spread="0.341"/>
                    <measurement group_id="O11" value="36.71" spread="0.404"/>
                    <measurement group_id="O12" value="36.61" spread="0.368"/>
                    <measurement group_id="O13" value="36.70" spread="0.362"/>
                    <measurement group_id="O14" value="36.61" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Body Temperature Within 7 Days After Dose 2</title>
        <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
        <time_frame>Days 28 through 34</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Body Temperature Within 7 Days After Dose 2</title>
          <description>Oral body temperature measurement is to be performed using the thermometer provided by the site for 7 days after each vaccination. The highest body temperature observed each day will be recorded on the Diary Card also provided by the site.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="27"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.54" spread="0.282"/>
                    <measurement group_id="O2" value="36.76" spread="0.301"/>
                    <measurement group_id="O3" value="36.68" spread="0.351"/>
                    <measurement group_id="O4" value="36.75" spread="0.466"/>
                    <measurement group_id="O5" value="36.60" spread="0.286"/>
                    <measurement group_id="O6" value="36.72" spread="0.317"/>
                    <measurement group_id="O7" value="36.71" spread="0.394"/>
                    <measurement group_id="O8" value="36.64" spread="0.342"/>
                    <measurement group_id="O9" value="36.59" spread="0.463"/>
                    <measurement group_id="O10" value="36.73" spread="0.293"/>
                    <measurement group_id="O11" value="36.68" spread="0.345"/>
                    <measurement group_id="O12" value="36.56" spread="0.351"/>
                    <measurement group_id="O13" value="36.76" spread="0.391"/>
                    <measurement group_id="O14" value="36.61" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.</description>
        <time_frame>Day 1 up to Day 56</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AEs are any AEs that are not solicited local or systemic AEs, as defined by this study.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.7"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="53.3"/>
                    <measurement group_id="O4" value="45.2"/>
                    <measurement group_id="O5" value="43.3"/>
                    <measurement group_id="O6" value="54.8"/>
                    <measurement group_id="O7" value="43.3"/>
                    <measurement group_id="O8" value="62.5"/>
                    <measurement group_id="O9" value="69.0"/>
                    <measurement group_id="O10" value="43.3"/>
                    <measurement group_id="O11" value="48.3"/>
                    <measurement group_id="O12" value="50.0"/>
                    <measurement group_id="O13" value="51.7"/>
                    <measurement group_id="O14" value="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
        <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>Day 1 up to Day 393</time_frame>
        <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serious Adverse Events (SAEs)</title>
          <description>A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
          <population>Safety population included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="3.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="9.4"/>
                    <measurement group_id="O9" value="3.4"/>
                    <measurement group_id="O10" value="3.3"/>
                    <measurement group_id="O11" value="3.4"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="3.4"/>
                    <measurement group_id="O14" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA)</title>
        <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
        <time_frame>Baseline and Days 28, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Seroresponse on Day 28, Day 208 and Day 393 (Pan-Ig ELISA)</title>
          <description>Seroresponse was defined as 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 virus-Like particle (VLP) and GII.4 VLP as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.3"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O12" value="71.4" lower_limit="51.3" upper_limit="86.8"/>
                    <measurement group_id="O13" value="79.3" lower_limit="60.3" upper_limit="92.0"/>
                    <measurement group_id="O14" value="67.7" lower_limit="48.6" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O2" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O3" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O4" value="19.4" lower_limit="7.5" upper_limit="37.5"/>
                    <measurement group_id="O5" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O6" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O7" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O8" value="34.4" lower_limit="18.6" upper_limit="53.2"/>
                    <measurement group_id="O9" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O10" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O11" value="14.8" lower_limit="4.2" upper_limit="33.7"/>
                    <measurement group_id="O12" value="32.1" lower_limit="15.9" upper_limit="52.4"/>
                    <measurement group_id="O13" value="34.5" lower_limit="17.9" upper_limit="54.3"/>
                    <measurement group_id="O14" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O2" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O3" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O4" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O5" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O6" value="13.8" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O7" value="10.3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O8" value="15.6" lower_limit="5.3" upper_limit="32.8"/>
                    <measurement group_id="O9" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O10" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O11" value="7.4" lower_limit="0.9" upper_limit="24.3"/>
                    <measurement group_id="O12" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O13" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O14" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in GI.1 VLP Antibody Titer (Pan-Ig ELISA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in GI.1 VLP Antibody Titer (Pan-Ig ELISA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O4" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O12" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O13" value="93.1" lower_limit="77.2" upper_limit="99.2"/>
                    <measurement group_id="O14" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                    <measurement group_id="O2" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O5" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                    <measurement group_id="O6" value="96.8" lower_limit="83.3" upper_limit="99.9"/>
                    <measurement group_id="O7" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O8" value="87.5" lower_limit="71.0" upper_limit="96.5"/>
                    <measurement group_id="O9" value="92.9" lower_limit="76.5" upper_limit="99.1"/>
                    <measurement group_id="O10" value="90.0" lower_limit="73.5" upper_limit="97.9"/>
                    <measurement group_id="O11" value="83.3" lower_limit="62.6" upper_limit="95.3"/>
                    <measurement group_id="O12" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O13" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O14" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                    <measurement group_id="O2" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O3" value="67.9" lower_limit="47.6" upper_limit="84.1"/>
                    <measurement group_id="O4" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O5" value="70.0" lower_limit="50.6" upper_limit="85.3"/>
                    <measurement group_id="O6" value="73.3" lower_limit="54.1" upper_limit="87.7"/>
                    <measurement group_id="O7" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O8" value="62.5" lower_limit="43.7" upper_limit="78.9"/>
                    <measurement group_id="O9" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O10" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                    <measurement group_id="O11" value="54.2" lower_limit="32.8" upper_limit="74.4"/>
                    <measurement group_id="O12" value="71.4" lower_limit="51.3" upper_limit="86.8"/>
                    <measurement group_id="O13" value="75.9" lower_limit="56.5" upper_limit="89.7"/>
                    <measurement group_id="O14" value="74.1" lower_limit="53.7" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" lower_limit="35.7" upper_limit="73.6"/>
                    <measurement group_id="O2" value="46.4" lower_limit="27.5" upper_limit="66.1"/>
                    <measurement group_id="O3" value="67.9" lower_limit="47.6" upper_limit="84.1"/>
                    <measurement group_id="O4" value="69.0" lower_limit="49.2" upper_limit="84.7"/>
                    <measurement group_id="O5" value="63.3" lower_limit="43.9" upper_limit="80.1"/>
                    <measurement group_id="O6" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O7" value="55.2" lower_limit="35.7" upper_limit="73.6"/>
                    <measurement group_id="O8" value="53.1" lower_limit="34.7" upper_limit="70.9"/>
                    <measurement group_id="O9" value="82.1" lower_limit="63.1" upper_limit="93.9"/>
                    <measurement group_id="O10" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                    <measurement group_id="O11" value="45.8" lower_limit="25.6" upper_limit="67.2"/>
                    <measurement group_id="O12" value="64.3" lower_limit="44.1" upper_limit="81.4"/>
                    <measurement group_id="O13" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O14" value="78.6" lower_limit="59.0" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA)</title>
        <description>The percentage of participants with a 4-fold rise or greater from in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in GII.4 VLP Antibody Titer (Pan-Ig ELISA)</title>
          <description>The percentage of participants with a 4-fold rise or greater from in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by pan immunoglobulin (Pan-Ig) enzyme-linked immunosorbent assay (ELISA).
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O10" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O12" value="78.6" lower_limit="59.0" upper_limit="91.7"/>
                    <measurement group_id="O13" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O14" value="70.0" lower_limit="50.6" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="31.3" upper_limit="68.7"/>
                    <measurement group_id="O2" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O3" value="46.4" lower_limit="27.5" upper_limit="66.1"/>
                    <measurement group_id="O4" value="41.4" lower_limit="23.5" upper_limit="61.1"/>
                    <measurement group_id="O5" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O6" value="71.0" lower_limit="52.0" upper_limit="85.8"/>
                    <measurement group_id="O7" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O8" value="71.9" lower_limit="53.3" upper_limit="86.3"/>
                    <measurement group_id="O9" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                    <measurement group_id="O10" value="73.3" lower_limit="54.1" upper_limit="87.7"/>
                    <measurement group_id="O11" value="54.2" lower_limit="32.8" upper_limit="74.4"/>
                    <measurement group_id="O12" value="78.6" lower_limit="59.0" upper_limit="91.7"/>
                    <measurement group_id="O13" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O14" value="63.3" lower_limit="43.9" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O2" value="27.6" lower_limit="12.7" upper_limit="47.2"/>
                    <measurement group_id="O3" value="7.1" lower_limit="0.9" upper_limit="23.5"/>
                    <measurement group_id="O4" value="27.6" lower_limit="12.7" upper_limit="47.2"/>
                    <measurement group_id="O5" value="36.7" lower_limit="19.9" upper_limit="56.1"/>
                    <measurement group_id="O6" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O7" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O8" value="46.9" lower_limit="29.1" upper_limit="65.3"/>
                    <measurement group_id="O9" value="14.3" lower_limit="4.0" upper_limit="32.7"/>
                    <measurement group_id="O10" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O11" value="16.7" lower_limit="4.7" upper_limit="37.4"/>
                    <measurement group_id="O12" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O13" value="41.4" lower_limit="23.5" upper_limit="61.1"/>
                    <measurement group_id="O14" value="33.3" lower_limit="16.5" upper_limit="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O2" value="32.1" lower_limit="15.9" upper_limit="52.4"/>
                    <measurement group_id="O3" value="10.7" lower_limit="2.3" upper_limit="28.2"/>
                    <measurement group_id="O4" value="27.6" lower_limit="12.7" upper_limit="47.2"/>
                    <measurement group_id="O5" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O6" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O7" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O8" value="21.9" lower_limit="9.3" upper_limit="40.0"/>
                    <measurement group_id="O9" value="10.7" lower_limit="2.3" upper_limit="28.2"/>
                    <measurement group_id="O10" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O11" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O12" value="28.6" lower_limit="13.2" upper_limit="48.7"/>
                    <measurement group_id="O13" value="27.6" lower_limit="12.7" upper_limit="47.2"/>
                    <measurement group_id="O14" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="833.4" spread="4.64"/>
                    <measurement group_id="O2" value="790.3" spread="4.50"/>
                    <measurement group_id="O3" value="636.7" spread="4.60"/>
                    <measurement group_id="O4" value="647.6" spread="5.17"/>
                    <measurement group_id="O5" value="625.3" spread="2.96"/>
                    <measurement group_id="O6" value="520.3" spread="4.99"/>
                    <measurement group_id="O7" value="890.5" spread="4.75"/>
                    <measurement group_id="O8" value="842.9" spread="4.92"/>
                    <measurement group_id="O9" value="677.2" spread="3.75"/>
                    <measurement group_id="O10" value="827.3" spread="4.82"/>
                    <measurement group_id="O11" value="856.7" spread="5.34"/>
                    <measurement group_id="O12" value="741.5" spread="5.28"/>
                    <measurement group_id="O13" value="897.5" spread="3.74"/>
                    <measurement group_id="O14" value="742.7" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="798.9" spread="4.66"/>
                    <measurement group_id="O2" value="737.9" spread="4.42"/>
                    <measurement group_id="O3" value="548.5" spread="4.47"/>
                    <measurement group_id="O4" value="806.6" spread="5.36"/>
                    <measurement group_id="O5" value="573.6" spread="3.08"/>
                    <measurement group_id="O6" value="514.6" spread="5.19"/>
                    <measurement group_id="O7" value="910.4" spread="4.37"/>
                    <measurement group_id="O8" value="821.5" spread="4.84"/>
                    <measurement group_id="O9" value="638.5" spread="3.90"/>
                    <measurement group_id="O10" value="780.6" spread="5.11"/>
                    <measurement group_id="O11" value="889.7" spread="5.34"/>
                    <measurement group_id="O12" value="14488.6" spread="3.00"/>
                    <measurement group_id="O13" value="20839.2" spread="1.96"/>
                    <measurement group_id="O14" value="15967.7" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14417.7" spread="2.74"/>
                    <measurement group_id="O2" value="14171.3" spread="2.76"/>
                    <measurement group_id="O3" value="17504.8" spread="2.64"/>
                    <measurement group_id="O4" value="14220.4" spread="3.23"/>
                    <measurement group_id="O5" value="13982.2" spread="2.33"/>
                    <measurement group_id="O6" value="18266.0" spread="1.99"/>
                    <measurement group_id="O7" value="16082.5" spread="2.07"/>
                    <measurement group_id="O8" value="15974.2" spread="3.95"/>
                    <measurement group_id="O9" value="25808.9" spread="2.55"/>
                    <measurement group_id="O10" value="15466.3" spread="2.59"/>
                    <measurement group_id="O11" value="14045.2" spread="2.94"/>
                    <measurement group_id="O12" value="12613.2" spread="2.46"/>
                    <measurement group_id="O13" value="17696.3" spread="1.92"/>
                    <measurement group_id="O14" value="12235.7" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5725.2" spread="2.37"/>
                    <measurement group_id="O2" value="5069.7" spread="2.48"/>
                    <measurement group_id="O3" value="6084.3" spread="2.43"/>
                    <measurement group_id="O4" value="5613.9" spread="2.68"/>
                    <measurement group_id="O5" value="4467.6" spread="2.05"/>
                    <measurement group_id="O6" value="5106.4" spread="2.06"/>
                    <measurement group_id="O7" value="5660.5" spread="2.22"/>
                    <measurement group_id="O8" value="7174.8" spread="2.47"/>
                    <measurement group_id="O9" value="7542.0" spread="2.28"/>
                    <measurement group_id="O10" value="5361.1" spread="2.37"/>
                    <measurement group_id="O11" value="5162.8" spread="2.18"/>
                    <measurement group_id="O12" value="6863.9" spread="2.27"/>
                    <measurement group_id="O13" value="7459.1" spread="1.72"/>
                    <measurement group_id="O14" value="5912.6" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3886.0" spread="2.98"/>
                    <measurement group_id="O2" value="3179.7" spread="2.78"/>
                    <measurement group_id="O3" value="4470.4" spread="2.55"/>
                    <measurement group_id="O4" value="5009.0" spread="2.80"/>
                    <measurement group_id="O5" value="3209.6" spread="2.54"/>
                    <measurement group_id="O6" value="3874.5" spread="2.55"/>
                    <measurement group_id="O7" value="4940.3" spread="2.48"/>
                    <measurement group_id="O8" value="4773.3" spread="2.62"/>
                    <measurement group_id="O9" value="5550.1" spread="2.70"/>
                    <measurement group_id="O10" value="3542.9" spread="2.54"/>
                    <measurement group_id="O11" value="3960.0" spread="2.55"/>
                    <measurement group_id="O12" value="4715.8" spread="2.51"/>
                    <measurement group_id="O13" value="5686.7" spread="2.17"/>
                    <measurement group_id="O14" value="4404.7" spread="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1106.6" spread="4.68"/>
                    <measurement group_id="O2" value="1249.2" spread="3.45"/>
                    <measurement group_id="O3" value="1477.7" spread="4.13"/>
                    <measurement group_id="O4" value="1109.2" spread="4.10"/>
                    <measurement group_id="O5" value="921.7" spread="3.15"/>
                    <measurement group_id="O6" value="1130.9" spread="4.18"/>
                    <measurement group_id="O7" value="1340.4" spread="4.08"/>
                    <measurement group_id="O8" value="1238.6" spread="3.92"/>
                    <measurement group_id="O9" value="1201.2" spread="3.57"/>
                    <measurement group_id="O10" value="1473.2" spread="3.88"/>
                    <measurement group_id="O11" value="1832.3" spread="2.69"/>
                    <measurement group_id="O12" value="977.7" spread="3.73"/>
                    <measurement group_id="O13" value="1324.4" spread="3.34"/>
                    <measurement group_id="O14" value="1647.0" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1016.8" spread="5.56"/>
                    <measurement group_id="O2" value="1232.6" spread="3.46"/>
                    <measurement group_id="O3" value="1540.6" spread="3.83"/>
                    <measurement group_id="O4" value="1110.4" spread="3.84"/>
                    <measurement group_id="O5" value="839.4" spread="3.04"/>
                    <measurement group_id="O6" value="1097.8" spread="4.14"/>
                    <measurement group_id="O7" value="1268.1" spread="3.68"/>
                    <measurement group_id="O8" value="1311.0" spread="3.98"/>
                    <measurement group_id="O9" value="1139.9" spread="3.48"/>
                    <measurement group_id="O10" value="1494.7" spread="3.05"/>
                    <measurement group_id="O11" value="1924.8" spread="2.52"/>
                    <measurement group_id="O12" value="8459.4" spread="2.19"/>
                    <measurement group_id="O13" value="12901.7" spread="2.12"/>
                    <measurement group_id="O14" value="11116.3" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4595.7" spread="3.00"/>
                    <measurement group_id="O2" value="8636.7" spread="2.05"/>
                    <measurement group_id="O3" value="5750.4" spread="2.15"/>
                    <measurement group_id="O4" value="4391.5" spread="2.66"/>
                    <measurement group_id="O5" value="7545.2" spread="2.61"/>
                    <measurement group_id="O6" value="7802.7" spread="2.03"/>
                    <measurement group_id="O7" value="3444.6" spread="2.92"/>
                    <measurement group_id="O8" value="9945.7" spread="2.98"/>
                    <measurement group_id="O9" value="5129.9" spread="2.91"/>
                    <measurement group_id="O10" value="10624.2" spread="2.15"/>
                    <measurement group_id="O11" value="10034.2" spread="1.96"/>
                    <measurement group_id="O12" value="6622.0" spread="2.22"/>
                    <measurement group_id="O13" value="9995.5" spread="2.13"/>
                    <measurement group_id="O14" value="8164.0" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2341.2" spread="3.93"/>
                    <measurement group_id="O2" value="3653.0" spread="2.24"/>
                    <measurement group_id="O3" value="2993.2" spread="3.61"/>
                    <measurement group_id="O4" value="2887.7" spread="2.78"/>
                    <measurement group_id="O5" value="2984.6" spread="2.62"/>
                    <measurement group_id="O6" value="3212.2" spread="2.44"/>
                    <measurement group_id="O7" value="2251.1" spread="3.15"/>
                    <measurement group_id="O8" value="5017.6" spread="2.82"/>
                    <measurement group_id="O9" value="2615.1" spread="2.91"/>
                    <measurement group_id="O10" value="4531.4" spread="2.21"/>
                    <measurement group_id="O11" value="4667.0" spread="2.20"/>
                    <measurement group_id="O12" value="3837.9" spread="2.30"/>
                    <measurement group_id="O13" value="4693.8" spread="2.52"/>
                    <measurement group_id="O14" value="4546.8" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2236.5" spread="3.84"/>
                    <measurement group_id="O2" value="3103.0" spread="3.03"/>
                    <measurement group_id="O3" value="2450.2" spread="2.87"/>
                    <measurement group_id="O4" value="2175.3" spread="2.91"/>
                    <measurement group_id="O5" value="1946.4" spread="2.51"/>
                    <measurement group_id="O6" value="2173.7" spread="2.73"/>
                    <measurement group_id="O7" value="2267.2" spread="3.29"/>
                    <measurement group_id="O8" value="2969.9" spread="2.92"/>
                    <measurement group_id="O9" value="1898.2" spread="3.41"/>
                    <measurement group_id="O10" value="2550.0" spread="2.29"/>
                    <measurement group_id="O11" value="2871.1" spread="2.43"/>
                    <measurement group_id="O12" value="2425.1" spread="2.46"/>
                    <measurement group_id="O13" value="3133.0" spread="2.50"/>
                    <measurement group_id="O14" value="3060.7" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.13"/>
                    <measurement group_id="O2" value="0.9" spread="1.18"/>
                    <measurement group_id="O3" value="0.8" spread="1.50"/>
                    <measurement group_id="O4" value="1.2" spread="2.85"/>
                    <measurement group_id="O5" value="0.9" spread="1.26"/>
                    <measurement group_id="O6" value="1.0" spread="1.16"/>
                    <measurement group_id="O7" value="1.0" spread="1.36"/>
                    <measurement group_id="O8" value="1.0" spread="1.18"/>
                    <measurement group_id="O9" value="0.9" spread="1.28"/>
                    <measurement group_id="O10" value="0.9" spread="1.28"/>
                    <measurement group_id="O11" value="1.0" spread="1.58"/>
                    <measurement group_id="O12" value="19.5" spread="3.73"/>
                    <measurement group_id="O13" value="23.2" spread="3.00"/>
                    <measurement group_id="O14" value="22.0" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="3.69"/>
                    <measurement group_id="O2" value="18.8" spread="3.46"/>
                    <measurement group_id="O3" value="25.8" spread="3.09"/>
                    <measurement group_id="O4" value="22.4" spread="4.38"/>
                    <measurement group_id="O5" value="22.4" spread="3.02"/>
                    <measurement group_id="O6" value="35.1" spread="3.88"/>
                    <measurement group_id="O7" value="18.1" spread="4.35"/>
                    <measurement group_id="O8" value="19.0" spread="3.67"/>
                    <measurement group_id="O9" value="36.5" spread="4.85"/>
                    <measurement group_id="O10" value="18.7" spread="3.31"/>
                    <measurement group_id="O11" value="13.5" spread="3.07"/>
                    <measurement group_id="O12" value="17.0" spread="3.63"/>
                    <measurement group_id="O13" value="19.7" spread="2.78"/>
                    <measurement group_id="O14" value="16.8" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="3.63"/>
                    <measurement group_id="O2" value="6.7" spread="3.71"/>
                    <measurement group_id="O3" value="9.3" spread="3.77"/>
                    <measurement group_id="O4" value="9.0" spread="4.32"/>
                    <measurement group_id="O5" value="7.1" spread="2.63"/>
                    <measurement group_id="O6" value="10.4" spread="3.79"/>
                    <measurement group_id="O7" value="6.4" spread="3.62"/>
                    <measurement group_id="O8" value="8.5" spread="3.90"/>
                    <measurement group_id="O9" value="10.7" spread="3.00"/>
                    <measurement group_id="O10" value="6.5" spread="2.96"/>
                    <measurement group_id="O11" value="5.2" spread="3.27"/>
                    <measurement group_id="O12" value="9.3" spread="3.57"/>
                    <measurement group_id="O13" value="8.3" spread="2.79"/>
                    <measurement group_id="O14" value="7.8" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="3.27"/>
                    <measurement group_id="O2" value="4.1" spread="4.46"/>
                    <measurement group_id="O3" value="7.0" spread="3.56"/>
                    <measurement group_id="O4" value="8.0" spread="4.65"/>
                    <measurement group_id="O5" value="5.1" spread="2.41"/>
                    <measurement group_id="O6" value="7.4" spread="3.36"/>
                    <measurement group_id="O7" value="5.3" spread="3.40"/>
                    <measurement group_id="O8" value="5.7" spread="3.41"/>
                    <measurement group_id="O9" value="7.8" spread="2.87"/>
                    <measurement group_id="O10" value="4.3" spread="2.58"/>
                    <measurement group_id="O11" value="4.0" spread="3.08"/>
                    <measurement group_id="O12" value="6.4" spread="4.07"/>
                    <measurement group_id="O13" value="6.3" spread="2.95"/>
                    <measurement group_id="O14" value="6.1" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.56"/>
                    <measurement group_id="O2" value="1.0" spread="1.14"/>
                    <measurement group_id="O3" value="1.0" spread="1.23"/>
                    <measurement group_id="O4" value="1.0" spread="1.21"/>
                    <measurement group_id="O5" value="0.9" spread="1.18"/>
                    <measurement group_id="O6" value="1.0" spread="1.13"/>
                    <measurement group_id="O7" value="0.9" spread="1.37"/>
                    <measurement group_id="O8" value="1.1" spread="1.57"/>
                    <measurement group_id="O9" value="1.0" spread="1.17"/>
                    <measurement group_id="O10" value="1.0" spread="1.58"/>
                    <measurement group_id="O11" value="1.0" spread="1.25"/>
                    <measurement group_id="O12" value="8.7" spread="3.25"/>
                    <measurement group_id="O13" value="9.7" spread="3.02"/>
                    <measurement group_id="O14" value="6.7" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="3.11"/>
                    <measurement group_id="O2" value="7.2" spread="2.98"/>
                    <measurement group_id="O3" value="4.0" spread="2.66"/>
                    <measurement group_id="O4" value="4.1" spread="2.97"/>
                    <measurement group_id="O5" value="8.2" spread="2.72"/>
                    <measurement group_id="O6" value="6.9" spread="3.31"/>
                    <measurement group_id="O7" value="2.6" spread="2.60"/>
                    <measurement group_id="O8" value="8.0" spread="3.36"/>
                    <measurement group_id="O9" value="4.0" spread="3.00"/>
                    <measurement group_id="O10" value="7.2" spread="3.38"/>
                    <measurement group_id="O11" value="4.7" spread="1.97"/>
                    <measurement group_id="O12" value="6.8" spread="2.99"/>
                    <measurement group_id="O13" value="7.5" spread="2.74"/>
                    <measurement group_id="O14" value="5.0" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.45"/>
                    <measurement group_id="O2" value="3.0" spread="2.74"/>
                    <measurement group_id="O3" value="1.9" spread="1.96"/>
                    <measurement group_id="O4" value="2.6" spread="2.50"/>
                    <measurement group_id="O5" value="3.2" spread="2.36"/>
                    <measurement group_id="O6" value="2.7" spread="2.21"/>
                    <measurement group_id="O7" value="1.7" spread="2.17"/>
                    <measurement group_id="O8" value="4.1" spread="2.45"/>
                    <measurement group_id="O9" value="2.0" spread="2.06"/>
                    <measurement group_id="O10" value="3.1" spread="2.61"/>
                    <measurement group_id="O11" value="2.2" spread="1.92"/>
                    <measurement group_id="O12" value="3.9" spread="2.70"/>
                    <measurement group_id="O13" value="3.5" spread="2.24"/>
                    <measurement group_id="O14" value="2.5" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.77"/>
                    <measurement group_id="O2" value="2.6" spread="3.20"/>
                    <measurement group_id="O3" value="1.7" spread="2.41"/>
                    <measurement group_id="O4" value="2.0" spread="2.33"/>
                    <measurement group_id="O5" value="2.1" spread="2.34"/>
                    <measurement group_id="O6" value="1.9" spread="1.99"/>
                    <measurement group_id="O7" value="1.6" spread="2.46"/>
                    <measurement group_id="O8" value="2.4" spread="2.40"/>
                    <measurement group_id="O9" value="1.5" spread="2.27"/>
                    <measurement group_id="O10" value="1.7" spread="2.41"/>
                    <measurement group_id="O11" value="1.4" spread="2.27"/>
                    <measurement group_id="O12" value="2.5" spread="2.60"/>
                    <measurement group_id="O13" value="2.4" spread="2.22"/>
                    <measurement group_id="O14" value="1.7" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)</title>
        <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP and GII.4 VLP Antibody Titers (IgA ELISA)</title>
          <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="3.03" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.3"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O12" value="71.4" lower_limit="51.3" upper_limit="86.8"/>
                    <measurement group_id="O13" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O14" value="64.5" lower_limit="45.4" upper_limit="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="34.3" upper_limit="71.7"/>
                    <measurement group_id="O2" value="58.6" lower_limit="38.9" upper_limit="76.5"/>
                    <measurement group_id="O3" value="39.3" lower_limit="21.5" upper_limit="59.4"/>
                    <measurement group_id="O4" value="45.2" lower_limit="27.3" upper_limit="64.0"/>
                    <measurement group_id="O5" value="70.0" lower_limit="50.6" upper_limit="85.3"/>
                    <measurement group_id="O6" value="58.1" lower_limit="39.1" upper_limit="75.5"/>
                    <measurement group_id="O7" value="36.7" lower_limit="19.9" upper_limit="56.1"/>
                    <measurement group_id="O8" value="65.6" lower_limit="46.8" upper_limit="81.4"/>
                    <measurement group_id="O9" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                    <measurement group_id="O10" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O11" value="50.0" lower_limit="29.9" upper_limit="70.1"/>
                    <measurement group_id="O12" value="57.1" lower_limit="37.2" upper_limit="75.5"/>
                    <measurement group_id="O13" value="51.7" lower_limit="32.5" upper_limit="70.6"/>
                    <measurement group_id="O14" value="46.7" lower_limit="28.3" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="30.0" lower_limit="14.7" upper_limit="49.4"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="25.0" lower_limit="11.5" upper_limit="43.4"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (IgA ELISA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O4" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O12" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O13" value="100.0" lower_limit="88.1" upper_limit="100.0"/>
                    <measurement group_id="O14" value="100.0" lower_limit="88.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                    <measurement group_id="O2" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O5" value="96.7" lower_limit="82.8" upper_limit="99.9"/>
                    <measurement group_id="O6" value="100.0" lower_limit="88.8" upper_limit="100.0"/>
                    <measurement group_id="O7" value="90.0" lower_limit="73.5" upper_limit="97.9"/>
                    <measurement group_id="O8" value="90.6" lower_limit="75.0" upper_limit="98.0"/>
                    <measurement group_id="O9" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O10" value="100.0" lower_limit="88.4" upper_limit="100.0"/>
                    <measurement group_id="O11" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                    <measurement group_id="O12" value="96.4" lower_limit="81.7" upper_limit="99.9"/>
                    <measurement group_id="O13" value="100.0" lower_limit="88.1" upper_limit="100.0"/>
                    <measurement group_id="O14" value="100.0" lower_limit="88.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="71.9" lower_limit="53.3" upper_limit="86.3"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="73.3" lower_limit="54.1" upper_limit="87.7"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="54.8" lower_limit="36.0" upper_limit="72.7"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)</title>
        <description>The percentage of participants with a 4-fold rise from or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (IgA ELISA)</title>
          <description>The percentage of participants with a 4-fold rise from or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by immunoglobulin A (IgA) enzyme-linked immunosorbent assay (ELISA) for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.7"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O10" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O12" value="75.0" lower_limit="55.1" upper_limit="89.3"/>
                    <measurement group_id="O13" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O14" value="63.3" lower_limit="43.9" upper_limit="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="34.3" upper_limit="71.7"/>
                    <measurement group_id="O2" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O3" value="39.3" lower_limit="21.5" upper_limit="59.4"/>
                    <measurement group_id="O4" value="51.7" lower_limit="32.5" upper_limit="70.6"/>
                    <measurement group_id="O5" value="73.3" lower_limit="54.1" upper_limit="87.7"/>
                    <measurement group_id="O6" value="58.1" lower_limit="39.1" upper_limit="75.5"/>
                    <measurement group_id="O7" value="36.7" lower_limit="19.9" upper_limit="56.1"/>
                    <measurement group_id="O8" value="68.8" lower_limit="50.0" upper_limit="83.9"/>
                    <measurement group_id="O9" value="46.4" lower_limit="27.5" upper_limit="66.1"/>
                    <measurement group_id="O10" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O11" value="54.2" lower_limit="32.8" upper_limit="74.4"/>
                    <measurement group_id="O12" value="60.7" lower_limit="40.6" upper_limit="78.5"/>
                    <measurement group_id="O13" value="51.7" lower_limit="32.5" upper_limit="70.6"/>
                    <measurement group_id="O14" value="46.7" lower_limit="28.3" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="36.7" lower_limit="19.9" upper_limit="56.1"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="34.4" lower_limit="18.6" upper_limit="53.2"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="16.1" lower_limit="5.5" upper_limit="33.7"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GI.1 VLP Antibody Titers (IgA ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9" spread="4.86"/>
                    <measurement group_id="O2" value="37.4" spread="3.59"/>
                    <measurement group_id="O3" value="42.1" spread="3.63"/>
                    <measurement group_id="O4" value="32.1" spread="5.26"/>
                    <measurement group_id="O5" value="30.1" spread="3.26"/>
                    <measurement group_id="O6" value="44.5" spread="6.06"/>
                    <measurement group_id="O7" value="53.6" spread="5.76"/>
                    <measurement group_id="O8" value="60.1" spread="6.45"/>
                    <measurement group_id="O9" value="36.8" spread="5.30"/>
                    <measurement group_id="O10" value="58.5" spread="4.08"/>
                    <measurement group_id="O11" value="47.0" spread="4.91"/>
                    <measurement group_id="O12" value="73.3" spread="5.24"/>
                    <measurement group_id="O13" value="40.8" spread="4.25"/>
                    <measurement group_id="O14" value="41.5" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="4.99"/>
                    <measurement group_id="O2" value="34.6" spread="3.38"/>
                    <measurement group_id="O3" value="41.2" spread="3.85"/>
                    <measurement group_id="O4" value="41.0" spread="4.38"/>
                    <measurement group_id="O5" value="29.4" spread="3.31"/>
                    <measurement group_id="O6" value="46.2" spread="6.22"/>
                    <measurement group_id="O7" value="54.4" spread="5.67"/>
                    <measurement group_id="O8" value="59.8" spread="6.23"/>
                    <measurement group_id="O9" value="37.8" spread="5.20"/>
                    <measurement group_id="O10" value="56.3" spread="3.95"/>
                    <measurement group_id="O11" value="57.0" spread="5.31"/>
                    <measurement group_id="O12" value="1649.9" spread="4.88"/>
                    <measurement group_id="O13" value="2148.2" spread="2.98"/>
                    <measurement group_id="O14" value="1703.2" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1358.4" spread="4.02"/>
                    <measurement group_id="O2" value="996.2" spread="5.02"/>
                    <measurement group_id="O3" value="2223.3" spread="2.91"/>
                    <measurement group_id="O4" value="1068.7" spread="5.39"/>
                    <measurement group_id="O5" value="1368.6" spread="3.99"/>
                    <measurement group_id="O6" value="1849.8" spread="3.35"/>
                    <measurement group_id="O7" value="1594.9" spread="4.87"/>
                    <measurement group_id="O8" value="1435.5" spread="7.02"/>
                    <measurement group_id="O9" value="2074.3" spread="4.40"/>
                    <measurement group_id="O10" value="1510.6" spread="4.45"/>
                    <measurement group_id="O11" value="1131.2" spread="4.28"/>
                    <measurement group_id="O12" value="810.7" spread="5.58"/>
                    <measurement group_id="O13" value="922.6" spread="3.73"/>
                    <measurement group_id="O14" value="848.2" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="302.5" spread="4.10"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="512.4" spread="5.85"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="224.0" spread="2.73"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="340.1" spread="3.91"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)</title>
        <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of GII.4 VLP Antibody Titers (IgA ELISA)</title>
          <description>Geometric mean titer (GMT) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" spread="6.63"/>
                    <measurement group_id="O2" value="113.6" spread="4.43"/>
                    <measurement group_id="O3" value="145.5" spread="4.72"/>
                    <measurement group_id="O4" value="119.5" spread="4.47"/>
                    <measurement group_id="O5" value="72.8" spread="4.64"/>
                    <measurement group_id="O6" value="114.6" spread="4.56"/>
                    <measurement group_id="O7" value="100.2" spread="4.47"/>
                    <measurement group_id="O8" value="133.0" spread="4.77"/>
                    <measurement group_id="O9" value="114.3" spread="4.65"/>
                    <measurement group_id="O10" value="158.5" spread="3.41"/>
                    <measurement group_id="O11" value="201.7" spread="3.30"/>
                    <measurement group_id="O12" value="105.9" spread="4.08"/>
                    <measurement group_id="O13" value="121.9" spread="4.16"/>
                    <measurement group_id="O14" value="174.5" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="6.49"/>
                    <measurement group_id="O2" value="110.0" spread="4.31"/>
                    <measurement group_id="O3" value="151.2" spread="4.70"/>
                    <measurement group_id="O4" value="125.3" spread="4.34"/>
                    <measurement group_id="O5" value="73.8" spread="4.42"/>
                    <measurement group_id="O6" value="116.3" spread="4.49"/>
                    <measurement group_id="O7" value="106.3" spread="4.05"/>
                    <measurement group_id="O8" value="139.2" spread="5.48"/>
                    <measurement group_id="O9" value="106.3" spread="4.71"/>
                    <measurement group_id="O10" value="164.8" spread="3.16"/>
                    <measurement group_id="O11" value="218.8" spread="3.07"/>
                    <measurement group_id="O12" value="953.5" spread="2.83"/>
                    <measurement group_id="O13" value="948.2" spread="2.52"/>
                    <measurement group_id="O14" value="1118.0" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495.7" spread="3.30"/>
                    <measurement group_id="O2" value="840.8" spread="2.87"/>
                    <measurement group_id="O3" value="583.7" spread="2.34"/>
                    <measurement group_id="O4" value="467.9" spread="2.79"/>
                    <measurement group_id="O5" value="803.3" spread="3.24"/>
                    <measurement group_id="O6" value="714.2" spread="2.44"/>
                    <measurement group_id="O7" value="336.7" spread="3.74"/>
                    <measurement group_id="O8" value="1088.9" spread="3.72"/>
                    <measurement group_id="O9" value="513.9" spread="3.82"/>
                    <measurement group_id="O10" value="1117.7" spread="3.03"/>
                    <measurement group_id="O11" value="1027.3" spread="2.36"/>
                    <measurement group_id="O12" value="578.8" spread="3.11"/>
                    <measurement group_id="O13" value="552.2" spread="2.60"/>
                    <measurement group_id="O14" value="691.2" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="251.8" spread="3.94"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="427.9" spread="3.95"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="139.7" spread="4.07"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="273.4" spread="3.59"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (IgA ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.52"/>
                    <measurement group_id="O2" value="0.9" spread="1.49"/>
                    <measurement group_id="O3" value="1.0" spread="1.23"/>
                    <measurement group_id="O4" value="1.3" spread="2.65"/>
                    <measurement group_id="O5" value="1.0" spread="1.23"/>
                    <measurement group_id="O6" value="1.0" spread="1.14"/>
                    <measurement group_id="O7" value="1.0" spread="1.44"/>
                    <measurement group_id="O8" value="1.0" spread="1.10"/>
                    <measurement group_id="O9" value="1.0" spread="1.13"/>
                    <measurement group_id="O10" value="1.0" spread="1.46"/>
                    <measurement group_id="O11" value="1.2" spread="1.86"/>
                    <measurement group_id="O12" value="22.5" spread="2.95"/>
                    <measurement group_id="O13" value="52.7" spread="2.79"/>
                    <measurement group_id="O14" value="42.3" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="4.46"/>
                    <measurement group_id="O2" value="28.0" spread="4.40"/>
                    <measurement group_id="O3" value="49.2" spread="2.81"/>
                    <measurement group_id="O4" value="34.2" spread="5.55"/>
                    <measurement group_id="O5" value="45.4" spread="3.47"/>
                    <measurement group_id="O6" value="41.5" spread="3.50"/>
                    <measurement group_id="O7" value="29.8" spread="4.63"/>
                    <measurement group_id="O8" value="23.9" spread="4.13"/>
                    <measurement group_id="O9" value="52.1" spread="3.61"/>
                    <measurement group_id="O10" value="25.8" spread="3.15"/>
                    <measurement group_id="O11" value="20.8" spread="2.77"/>
                    <measurement group_id="O12" value="11.1" spread="2.19"/>
                    <measurement group_id="O13" value="22.6" spread="2.29"/>
                    <measurement group_id="O14" value="21.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="10.0" spread="2.89"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="8.5" spread="3.77"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="7.4" spread="2.41"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="5.2" spread="3.34"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (IgA ELISA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by IgA ELISA for all arms on day 28 and day 56 and for selected arms on day 208 and day 393.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.33"/>
                    <measurement group_id="O2" value="1.0" spread="1.42"/>
                    <measurement group_id="O3" value="1.0" spread="1.13"/>
                    <measurement group_id="O4" value="1.1" spread="1.27"/>
                    <measurement group_id="O5" value="1.0" spread="1.14"/>
                    <measurement group_id="O6" value="1.0" spread="1.09"/>
                    <measurement group_id="O7" value="1.1" spread="1.44"/>
                    <measurement group_id="O8" value="1.0" spread="1.60"/>
                    <measurement group_id="O9" value="1.0" spread="1.10"/>
                    <measurement group_id="O10" value="1.0" spread="1.36"/>
                    <measurement group_id="O11" value="1.0" spread="1.22"/>
                    <measurement group_id="O12" value="9.0" spread="2.85"/>
                    <measurement group_id="O13" value="7.8" spread="2.89"/>
                    <measurement group_id="O14" value="6.3" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="4.37"/>
                    <measurement group_id="O2" value="7.7" spread="3.92"/>
                    <measurement group_id="O3" value="3.6" spread="2.45"/>
                    <measurement group_id="O4" value="4.2" spread="2.54"/>
                    <measurement group_id="O5" value="11.0" spread="3.48"/>
                    <measurement group_id="O6" value="6.2" spread="3.36"/>
                    <measurement group_id="O7" value="3.4" spread="2.70"/>
                    <measurement group_id="O8" value="8.2" spread="3.36"/>
                    <measurement group_id="O9" value="4.0" spread="3.14"/>
                    <measurement group_id="O10" value="7.1" spread="2.81"/>
                    <measurement group_id="O11" value="4.9" spread="2.35"/>
                    <measurement group_id="O12" value="5.5" spread="4.74"/>
                    <measurement group_id="O13" value="4.5" spread="2.53"/>
                    <measurement group_id="O14" value="3.9" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="3.5" spread="2.67"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="3.2" spread="2.44"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,31,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="1.9" spread="2.47"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="1.9" spread="2.26"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA)</title>
        <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Antibody Titers for GI.1 VLP and GII.4 VLP(HBGA)</title>
          <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP as measured by histoblood group antigen (HBGA) binding assay.
D=Day</description>
          <population>Full Analysis Set included all randomized participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.3"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O12" value="67.9" lower_limit="47.6" upper_limit="84.1"/>
                    <measurement group_id="O13" value="62.1" lower_limit="42.3" upper_limit="79.3"/>
                    <measurement group_id="O14" value="67.7" lower_limit="48.6" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O2" value="55.2" lower_limit="35.7" upper_limit="73.6"/>
                    <measurement group_id="O3" value="32.1" lower_limit="15.9" upper_limit="52.4"/>
                    <measurement group_id="O4" value="35.5" lower_limit="19.2" upper_limit="54.6"/>
                    <measurement group_id="O5" value="66.7" lower_limit="47.2" upper_limit="82.7"/>
                    <measurement group_id="O6" value="51.6" lower_limit="33.1" upper_limit="69.8"/>
                    <measurement group_id="O7" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                    <measurement group_id="O8" value="59.4" lower_limit="40.6" upper_limit="76.3"/>
                    <measurement group_id="O9" value="28.6" lower_limit="13.2" upper_limit="48.7"/>
                    <measurement group_id="O10" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                    <measurement group_id="O11" value="53.8" lower_limit="33.4" upper_limit="73.4"/>
                    <measurement group_id="O12" value="75.0" lower_limit="55.1" upper_limit="89.3"/>
                    <measurement group_id="O13" value="58.6" lower_limit="38.9" upper_limit="76.5"/>
                    <measurement group_id="O14" value="56.7" lower_limit="37.4" upper_limit="74.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="2.1" upper_limit="26.5"/>
                    <measurement group_id="O2" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O3" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O4" value="6.5" lower_limit="0.8" upper_limit="21.4"/>
                    <measurement group_id="O5" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O6" value="13.3" lower_limit="3.8" upper_limit="30.7"/>
                    <measurement group_id="O7" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O8" value="31.3" lower_limit="16.1" upper_limit="50.0"/>
                    <measurement group_id="O9" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O10" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O11" value="7.4" lower_limit="0.9" upper_limit="24.3"/>
                    <measurement group_id="O12" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                    <measurement group_id="O13" value="34.5" lower_limit="17.9" upper_limit="54.3"/>
                    <measurement group_id="O14" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="13.8" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O3" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O4" value="3.2" lower_limit="0.1" upper_limit="16.7"/>
                    <measurement group_id="O5" value="6.7" lower_limit="0.8" upper_limit="22.1"/>
                    <measurement group_id="O6" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O7" value="6.9" lower_limit="0.8" upper_limit="22.8"/>
                    <measurement group_id="O8" value="9.4" lower_limit="2.0" upper_limit="25.0"/>
                    <measurement group_id="O9" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O10" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O11" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                    <measurement group_id="O12" value="7.1" lower_limit="0.9" upper_limit="23.5"/>
                    <measurement group_id="O13" value="10.3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O14" value="7.1" lower_limit="0.9" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GI.1 VLP Antibody Titers (HBGA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GI.1 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O5" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="0" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O9" value="0" lower_limit="0.0" upper_limit="12.8"/>
                    <measurement group_id="O10" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O12" value="82.1" lower_limit="63.1" upper_limit="93.9"/>
                    <measurement group_id="O13" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O14" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                    <measurement group_id="O2" value="79.3" lower_limit="60.3" upper_limit="92.0"/>
                    <measurement group_id="O3" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O4" value="82.8" lower_limit="64.2" upper_limit="94.2"/>
                    <measurement group_id="O5" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O6" value="87.1" lower_limit="70.2" upper_limit="96.4"/>
                    <measurement group_id="O7" value="76.7" lower_limit="57.7" upper_limit="90.1"/>
                    <measurement group_id="O8" value="78.1" lower_limit="60.0" upper_limit="90.7"/>
                    <measurement group_id="O9" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O10" value="90.0" lower_limit="73.5" upper_limit="97.9"/>
                    <measurement group_id="O11" value="70.8" lower_limit="48.9" upper_limit="87.4"/>
                    <measurement group_id="O12" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O13" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                    <measurement group_id="O14" value="93.3" lower_limit="77.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3" lower_limit="34.3" upper_limit="71.7"/>
                    <measurement group_id="O2" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O3" value="67.9" lower_limit="47.6" upper_limit="84.1"/>
                    <measurement group_id="O4" value="58.6" lower_limit="38.9" upper_limit="76.5"/>
                    <measurement group_id="O5" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                    <measurement group_id="O6" value="70.0" lower_limit="50.6" upper_limit="85.3"/>
                    <measurement group_id="O7" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                    <measurement group_id="O8" value="78.1" lower_limit="60.0" upper_limit="90.7"/>
                    <measurement group_id="O9" value="82.1" lower_limit="63.1" upper_limit="93.9"/>
                    <measurement group_id="O10" value="56.7" lower_limit="37.4" upper_limit="74.5"/>
                    <measurement group_id="O11" value="33.3" lower_limit="15.6" upper_limit="55.3"/>
                    <measurement group_id="O12" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O13" value="93.1" lower_limit="77.2" upper_limit="99.2"/>
                    <measurement group_id="O14" value="77.8" lower_limit="57.7" upper_limit="91.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="15.3" upper_limit="50.8"/>
                    <measurement group_id="O2" value="32.1" lower_limit="15.9" upper_limit="52.4"/>
                    <measurement group_id="O3" value="50.0" lower_limit="30.6" upper_limit="69.4"/>
                    <measurement group_id="O4" value="37.9" lower_limit="20.7" upper_limit="57.7"/>
                    <measurement group_id="O5" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O6" value="37.9" lower_limit="20.7" upper_limit="57.7"/>
                    <measurement group_id="O7" value="44.8" lower_limit="26.4" upper_limit="64.3"/>
                    <measurement group_id="O8" value="53.1" lower_limit="34.7" upper_limit="70.9"/>
                    <measurement group_id="O9" value="53.6" lower_limit="33.9" upper_limit="72.5"/>
                    <measurement group_id="O10" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                    <measurement group_id="O11" value="29.2" lower_limit="12.6" upper_limit="51.1"/>
                    <measurement group_id="O12" value="50.0" lower_limit="30.6" upper_limit="69.4"/>
                    <measurement group_id="O13" value="51.7" lower_limit="32.5" upper_limit="70.6"/>
                    <measurement group_id="O14" value="46.4" lower_limit="27.5" upper_limit="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</title>
        <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Baseline and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum GII.4 VLP Antibody Titers (HBGA)</title>
          <description>The percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for GII.4 virus-like particle (VLP) as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of study drug and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O3" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                    <measurement group_id="O4" value="0" lower_limit="0.0" upper_limit="11.9"/>
                    <measurement group_id="O5" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O6" value="0" lower_limit="0.0" upper_limit="11.2"/>
                    <measurement group_id="O7" value="0" lower_limit="0.0" upper_limit="11.6"/>
                    <measurement group_id="O8" value="3.1" lower_limit="0.1" upper_limit="16.2"/>
                    <measurement group_id="O9" value="3.7" lower_limit="0.1" upper_limit="19.0"/>
                    <measurement group_id="O10" value="3.3" lower_limit="0.1" upper_limit="17.2"/>
                    <measurement group_id="O11" value="0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O12" value="82.1" lower_limit="63.1" upper_limit="93.9"/>
                    <measurement group_id="O13" value="65.5" lower_limit="45.7" upper_limit="82.1"/>
                    <measurement group_id="O14" value="70.0" lower_limit="50.6" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" lower_limit="28.3" upper_limit="65.7"/>
                    <measurement group_id="O2" value="72.4" lower_limit="52.8" upper_limit="87.3"/>
                    <measurement group_id="O3" value="39.3" lower_limit="21.5" upper_limit="59.4"/>
                    <measurement group_id="O4" value="41.4" lower_limit="23.5" upper_limit="61.1"/>
                    <measurement group_id="O5" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                    <measurement group_id="O6" value="61.3" lower_limit="42.2" upper_limit="78.2"/>
                    <measurement group_id="O7" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                    <measurement group_id="O8" value="71.9" lower_limit="53.3" upper_limit="86.3"/>
                    <measurement group_id="O9" value="35.7" lower_limit="18.6" upper_limit="55.9"/>
                    <measurement group_id="O10" value="63.3" lower_limit="43.9" upper_limit="80.1"/>
                    <measurement group_id="O11" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                    <measurement group_id="O12" value="75.0" lower_limit="55.1" upper_limit="89.3"/>
                    <measurement group_id="O13" value="58.6" lower_limit="38.9" upper_limit="76.5"/>
                    <measurement group_id="O14" value="60.0" lower_limit="40.6" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" lower_limit="12.3" upper_limit="45.9"/>
                    <measurement group_id="O2" value="31.0" lower_limit="15.3" upper_limit="50.8"/>
                    <measurement group_id="O3" value="17.9" lower_limit="6.1" upper_limit="36.9"/>
                    <measurement group_id="O4" value="20.7" lower_limit="8.0" upper_limit="39.7"/>
                    <measurement group_id="O5" value="43.3" lower_limit="25.5" upper_limit="62.6"/>
                    <measurement group_id="O6" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O7" value="20.0" lower_limit="7.7" upper_limit="38.6"/>
                    <measurement group_id="O8" value="43.8" lower_limit="26.4" upper_limit="62.3"/>
                    <measurement group_id="O9" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O10" value="33.3" lower_limit="17.3" upper_limit="52.8"/>
                    <measurement group_id="O11" value="25.0" lower_limit="9.8" upper_limit="46.7"/>
                    <measurement group_id="O12" value="50.0" lower_limit="30.6" upper_limit="69.4"/>
                    <measurement group_id="O13" value="37.9" lower_limit="20.7" upper_limit="57.7"/>
                    <measurement group_id="O14" value="22.2" lower_limit="8.6" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="3.9" upper_limit="31.7"/>
                    <measurement group_id="O2" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O3" value="3.6" lower_limit="0.1" upper_limit="18.3"/>
                    <measurement group_id="O4" value="17.2" lower_limit="5.8" upper_limit="35.8"/>
                    <measurement group_id="O5" value="23.3" lower_limit="9.9" upper_limit="42.3"/>
                    <measurement group_id="O6" value="3.4" lower_limit="0.1" upper_limit="17.8"/>
                    <measurement group_id="O7" value="10.3" lower_limit="2.2" upper_limit="27.4"/>
                    <measurement group_id="O8" value="12.5" lower_limit="3.5" upper_limit="29.0"/>
                    <measurement group_id="O9" value="10.7" lower_limit="2.3" upper_limit="28.2"/>
                    <measurement group_id="O10" value="16.7" lower_limit="5.6" upper_limit="34.7"/>
                    <measurement group_id="O11" value="4.2" lower_limit="0.1" upper_limit="21.1"/>
                    <measurement group_id="O12" value="21.4" lower_limit="8.3" upper_limit="41.0"/>
                    <measurement group_id="O13" value="24.1" lower_limit="10.3" upper_limit="43.5"/>
                    <measurement group_id="O14" value="10.7" lower_limit="2.3" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Baseline (Day 1) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of Anti-Norovirus GI.1 VLP Antibody Titers (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Full Analysis Set included all participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="2.75"/>
                    <measurement group_id="O2" value="18.7" spread="1.85"/>
                    <measurement group_id="O3" value="26.0" spread="2.73"/>
                    <measurement group_id="O4" value="26.8" spread="3.35"/>
                    <measurement group_id="O5" value="19.1" spread="1.68"/>
                    <measurement group_id="O6" value="24.8" spread="2.31"/>
                    <measurement group_id="O7" value="30.5" spread="3.04"/>
                    <measurement group_id="O8" value="24.5" spread="2.59"/>
                    <measurement group_id="O9" value="23.8" spread="2.46"/>
                    <measurement group_id="O10" value="23.2" spread="2.19"/>
                    <measurement group_id="O11" value="26.3" spread="2.68"/>
                    <measurement group_id="O12" value="23.1" spread="2.25"/>
                    <measurement group_id="O13" value="22.3" spread="2.26"/>
                    <measurement group_id="O14" value="20.6" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="2.60"/>
                    <measurement group_id="O2" value="18.6" spread="1.86"/>
                    <measurement group_id="O3" value="23.8" spread="2.44"/>
                    <measurement group_id="O4" value="26.7" spread="3.19"/>
                    <measurement group_id="O5" value="18.6" spread="1.70"/>
                    <measurement group_id="O6" value="23.0" spread="2.24"/>
                    <measurement group_id="O7" value="27.3" spread="2.46"/>
                    <measurement group_id="O8" value="25.1" spread="2.52"/>
                    <measurement group_id="O9" value="25.5" spread="2.52"/>
                    <measurement group_id="O10" value="24.8" spread="2.37"/>
                    <measurement group_id="O11" value="28.5" spread="2.66"/>
                    <measurement group_id="O12" value="347.6" spread="4.62"/>
                    <measurement group_id="O13" value="385.9" spread="3.64"/>
                    <measurement group_id="O14" value="391.1" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280.5" spread="3.94"/>
                    <measurement group_id="O2" value="236.3" spread="4.61"/>
                    <measurement group_id="O3" value="403.3" spread="3.74"/>
                    <measurement group_id="O4" value="286.9" spread="5.01"/>
                    <measurement group_id="O5" value="22.86" spread="3.94"/>
                    <measurement group_id="O6" value="356.4" spread="3.74"/>
                    <measurement group_id="O7" value="400.1" spread="3.33"/>
                    <measurement group_id="O8" value="412.9" spread="4.78"/>
                    <measurement group_id="O9" value="510.0" spread="4.36"/>
                    <measurement group_id="O10" value="247.2" spread="3.43"/>
                    <measurement group_id="O11" value="271.3" spread="5.00"/>
                    <measurement group_id="O12" value="398.6" spread="2.70"/>
                    <measurement group_id="O13" value="463.5" spread="2.32"/>
                    <measurement group_id="O14" value="355.8" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.0" spread="3.38"/>
                    <measurement group_id="O2" value="98.2" spread="3.46"/>
                    <measurement group_id="O3" value="159.0" spread="3.23"/>
                    <measurement group_id="O4" value="136.4" spread="3.67"/>
                    <measurement group_id="O5" value="80.1" spread="3.49"/>
                    <measurement group_id="O6" value="139.3" spread="2.68"/>
                    <measurement group_id="O7" value="159.8" spread="2.73"/>
                    <measurement group_id="O8" value="202.1" spread="3.34"/>
                    <measurement group_id="O9" value="208.6" spread="3.28"/>
                    <measurement group_id="O10" value="114.5" spread="2.89"/>
                    <measurement group_id="O11" value="107.9" spread="3.28"/>
                    <measurement group_id="O12" value="196.4" spread="2.86"/>
                    <measurement group_id="O13" value="219.2" spread="2.29"/>
                    <measurement group_id="O14" value="182.0" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="3.78"/>
                    <measurement group_id="O2" value="51.3" spread="3.23"/>
                    <measurement group_id="O3" value="88.1" spread="3.54"/>
                    <measurement group_id="O4" value="74.8" spread="4.26"/>
                    <measurement group_id="O5" value="44.0" spread="3.39"/>
                    <measurement group_id="O6" value="71.9" spread="3.40"/>
                    <measurement group_id="O7" value="91.5" spread="3.14"/>
                    <measurement group_id="O8" value="107.5" spread="3.97"/>
                    <measurement group_id="O9" value="99.6" spread="4.09"/>
                    <measurement group_id="O10" value="55.0" spread="3.22"/>
                    <measurement group_id="O11" value="66.1" spread="3.86"/>
                    <measurement group_id="O12" value="103.4" spread="3.95"/>
                    <measurement group_id="O13" value="113.6" spread="3.30"/>
                    <measurement group_id="O14" value="81.0" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Full Analysis Set included all participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of GII.4 VLP Antibody Titers (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Full Analysis Set included all participants who received at least one dose of trial vaccine. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,30,30,31,30,31,30,32,29,30,29,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="4.85"/>
                    <measurement group_id="O2" value="80.1" spread="3.44"/>
                    <measurement group_id="O3" value="115.3" spread="4.24"/>
                    <measurement group_id="O4" value="91.4" spread="4.15"/>
                    <measurement group_id="O5" value="60.9" spread="3.84"/>
                    <measurement group_id="O6" value="96.6" spread="4.03"/>
                    <measurement group_id="O7" value="80.7" spread="4.48"/>
                    <measurement group_id="O8" value="89.8" spread="4.41"/>
                    <measurement group_id="O9" value="96.2" spread="3.93"/>
                    <measurement group_id="O10" value="102.3" spread="3.39"/>
                    <measurement group_id="O11" value="121.9" spread="3.47"/>
                    <measurement group_id="O12" value="56.1" spread="3.48"/>
                    <measurement group_id="O13" value="92.0" spread="3.96"/>
                    <measurement group_id="O14" value="117.8" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,30,29,31,30,31,30,32,28,30,27,28,29,31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" spread="4.56"/>
                    <measurement group_id="O2" value="75.7" spread="3.63"/>
                    <measurement group_id="O3" value="124.9" spread="3.98"/>
                    <measurement group_id="O4" value="87.9" spread="3.75"/>
                    <measurement group_id="O5" value="67.7" spread="3.76"/>
                    <measurement group_id="O6" value="94.5" spread="4.30"/>
                    <measurement group_id="O7" value="74.6" spread="4.17"/>
                    <measurement group_id="O8" value="98.1" spread="5.11"/>
                    <measurement group_id="O9" value="92.9" spread="3.87"/>
                    <measurement group_id="O10" value="123.3" spread="3.25"/>
                    <measurement group_id="O11" value="117.6" spread="3.62"/>
                    <measurement group_id="O12" value="552.6" spread="3.65"/>
                    <measurement group_id="O13" value="688.4" spread="3.16"/>
                    <measurement group_id="O14" value="904.4" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,31,30,31,30,32,28,30,26,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.9" spread="3.40"/>
                    <measurement group_id="O2" value="686.3" spread="3.47"/>
                    <measurement group_id="O3" value="429.0" spread="2.40"/>
                    <measurement group_id="O4" value="317.8" spread="2.94"/>
                    <measurement group_id="O5" value="675.7" spread="3.21"/>
                    <measurement group_id="O6" value="632.1" spread="2.11"/>
                    <measurement group_id="O7" value="189.2" spread="4.63"/>
                    <measurement group_id="O8" value="842.8" spread="3.23"/>
                    <measurement group_id="O9" value="360.1" spread="3.85"/>
                    <measurement group_id="O10" value="862.8" spread="3.12"/>
                    <measurement group_id="O11" value="778.0" spread="2.57"/>
                    <measurement group_id="O12" value="426.5" spread="3.46"/>
                    <measurement group_id="O13" value="596.3" spread="2.86"/>
                    <measurement group_id="O14" value="604.4" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,30,31,30,30,30,32,29,30,27,28,29,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.7" spread="3.19"/>
                    <measurement group_id="O2" value="241.5" spread="3.24"/>
                    <measurement group_id="O3" value="244.6" spread="2.78"/>
                    <measurement group_id="O4" value="206.3" spread="2.84"/>
                    <measurement group_id="O5" value="229.9" spread="3.60"/>
                    <measurement group_id="O6" value="259.7" spread="2.66"/>
                    <measurement group_id="O7" value="142.5" spread="4.09"/>
                    <measurement group_id="O8" value="346.8" spread="2.92"/>
                    <measurement group_id="O9" value="201.0" spread="3.49"/>
                    <measurement group_id="O10" value="340.6" spread="2.60"/>
                    <measurement group_id="O11" value="324.6" spread="3.07"/>
                    <measurement group_id="O12" value="277.5" spread="2.53"/>
                    <measurement group_id="O13" value="350.9" spread="2.36"/>
                    <measurement group_id="O14" value="295.3" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,29,30,31,30,29,29,32,29,30,27,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.5" spread="4.21"/>
                    <measurement group_id="O2" value="180.2" spread="3.95"/>
                    <measurement group_id="O3" value="123.5" spread="3.87"/>
                    <measurement group_id="O4" value="133.2" spread="3.81"/>
                    <measurement group_id="O5" value="104.7" spread="4.01"/>
                    <measurement group_id="O6" value="134.4" spread="3.74"/>
                    <measurement group_id="O7" value="109.3" spread="4.44"/>
                    <measurement group_id="O8" value="182.9" spread="3.60"/>
                    <measurement group_id="O9" value="121.9" spread="3.88"/>
                    <measurement group_id="O10" value="179.7" spread="2.53"/>
                    <measurement group_id="O11" value="209.0" spread="3.38"/>
                    <measurement group_id="O12" value="126.2" spread="3.56"/>
                    <measurement group_id="O13" value="171.2" spread="3.61"/>
                    <measurement group_id="O14" value="192.9" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GI.1 VLP Antibody Titers (HBGA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GI.1 VLP antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.30"/>
                    <measurement group_id="O2" value="1.0" spread="1.08"/>
                    <measurement group_id="O3" value="0.9" spread="1.30"/>
                    <measurement group_id="O4" value="1.0" spread="1.21"/>
                    <measurement group_id="O5" value="1.0" spread="1.37"/>
                    <measurement group_id="O6" value="0.9" spread="1.26"/>
                    <measurement group_id="O7" value="0.9" spread="1.59"/>
                    <measurement group_id="O8" value="1.0" spread="1.22"/>
                    <measurement group_id="O9" value="1.1" spread="1.37"/>
                    <measurement group_id="O10" value="1.1" spread="1.28"/>
                    <measurement group_id="O11" value="1.0" spread="1.31"/>
                    <measurement group_id="O12" value="15.0" spread="3.80"/>
                    <measurement group_id="O13" value="17.3" spread="3.02"/>
                    <measurement group_id="O14" value="19.3" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="4.25"/>
                    <measurement group_id="O2" value="13.2" spread="4.31"/>
                    <measurement group_id="O3" value="14.9" spread="3.54"/>
                    <measurement group_id="O4" value="10.0" spread="4.07"/>
                    <measurement group_id="O5" value="12.0" spread="3.36"/>
                    <measurement group_id="O6" value="14.3" spread="2.98"/>
                    <measurement group_id="O7" value="13.1" spread="3.96"/>
                    <measurement group_id="O8" value="16.9" spread="4.60"/>
                    <measurement group_id="O9" value="21.1" spread="3.72"/>
                    <measurement group_id="O10" value="10.7" spread="2.53"/>
                    <measurement group_id="O11" value="9.7" spread="4.29"/>
                    <measurement group_id="O12" value="17.2" spread="2.36"/>
                    <measurement group_id="O13" value="20.8" spread="2.20"/>
                    <measurement group_id="O14" value="17.9" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="3.41"/>
                    <measurement group_id="O2" value="5.5" spread="3.18"/>
                    <measurement group_id="O3" value="6.0" spread="2.97"/>
                    <measurement group_id="O4" value="4.8" spread="2.91"/>
                    <measurement group_id="O5" value="4.2" spread="2.94"/>
                    <measurement group_id="O6" value="5.9" spread="2.00"/>
                    <measurement group_id="O7" value="5.2" spread="2.69"/>
                    <measurement group_id="O8" value="8.2" spread="3.14"/>
                    <measurement group_id="O9" value="8.6" spread="2.63"/>
                    <measurement group_id="O10" value="4.9" spread="2.24"/>
                    <measurement group_id="O11" value="3.7" spread="2.95"/>
                    <measurement group_id="O12" value="8.5" spread="2.52"/>
                    <measurement group_id="O13" value="9.8" spread="2.18"/>
                    <measurement group_id="O14" value="7.9" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="3.29"/>
                    <measurement group_id="O2" value="2.7" spread="2.71"/>
                    <measurement group_id="O3" value="3.3" spread="2.87"/>
                    <measurement group_id="O4" value="2.6" spread="2.97"/>
                    <measurement group_id="O5" value="2.3" spread="2.65"/>
                    <measurement group_id="O6" value="3.0" spread="2.35"/>
                    <measurement group_id="O7" value="2.9" spread="2.61"/>
                    <measurement group_id="O8" value="4.4" spread="3.30"/>
                    <measurement group_id="O9" value="4.0" spread="3.10"/>
                    <measurement group_id="O10" value="2.4" spread="2.35"/>
                    <measurement group_id="O11" value="2.4" spread="2.73"/>
                    <measurement group_id="O12" value="4.5" spread="3.29"/>
                    <measurement group_id="O13" value="5.1" spread="2.81"/>
                    <measurement group_id="O14" value="3.8" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</title>
        <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of GII.4 VLP Antibody Titers (HBGA)</title>
          <description>Geometric mean fold rise (GMFR) of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.68"/>
                    <measurement group_id="O2" value="0.9" spread="1.59"/>
                    <measurement group_id="O3" value="1.0" spread="1.47"/>
                    <measurement group_id="O4" value="1.0" spread="1.73"/>
                    <measurement group_id="O5" value="1.1" spread="1.62"/>
                    <measurement group_id="O6" value="1.0" spread="1.38"/>
                    <measurement group_id="O7" value="0.9" spread="1.29"/>
                    <measurement group_id="O8" value="1.1" spread="1.89"/>
                    <measurement group_id="O9" value="1.0" spread="1.59"/>
                    <measurement group_id="O10" value="1.2" spread="2.45"/>
                    <measurement group_id="O11" value="1.0" spread="1.46"/>
                    <measurement group_id="O12" value="9.8" spread="3.48"/>
                    <measurement group_id="O13" value="7.5" spread="3.13"/>
                    <measurement group_id="O14" value="7.0" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="4.42"/>
                    <measurement group_id="O2" value="8.9" spread="3.31"/>
                    <measurement group_id="O3" value="3.6" spread="2.71"/>
                    <measurement group_id="O4" value="3.7" spread="3.43"/>
                    <measurement group_id="O5" value="11.1" spread="3.32"/>
                    <measurement group_id="O6" value="6.5" spread="3.33"/>
                    <measurement group_id="O7" value="2.3" spread="2.95"/>
                    <measurement group_id="O8" value="9.4" spread="3.95"/>
                    <measurement group_id="O9" value="3.5" spread="3.61"/>
                    <measurement group_id="O10" value="8.4" spread="3.59"/>
                    <measurement group_id="O11" value="6.0" spread="2.24"/>
                    <measurement group_id="O12" value="7.6" spread="3.19"/>
                    <measurement group_id="O13" value="6.5" spread="2.94"/>
                    <measurement group_id="O14" value="4.8" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=30,29,28,29,30,30,30,32,28,30,24,28,29,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="3.10"/>
                    <measurement group_id="O2" value="3.1" spread="2.51"/>
                    <measurement group_id="O3" value="2.0" spread="2.42"/>
                    <measurement group_id="O4" value="2.4" spread="2.58"/>
                    <measurement group_id="O5" value="3.8" spread="2.56"/>
                    <measurement group_id="O6" value="2.5" spread="1.99"/>
                    <measurement group_id="O7" value="1.8" spread="2.27"/>
                    <measurement group_id="O8" value="3.9" spread="3.03"/>
                    <measurement group_id="O9" value="2.0" spread="2.30"/>
                    <measurement group_id="O10" value="3.3" spread="2.66"/>
                    <measurement group_id="O11" value="2.5" spread="1.73"/>
                    <measurement group_id="O12" value="4.9" spread="2.72"/>
                    <measurement group_id="O13" value="3.8" spread="2.81"/>
                    <measurement group_id="O14" value="2.5" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=29,28,28,29,30,29,29,32,28,30,24,28,29,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="3.14"/>
                    <measurement group_id="O2" value="2.3" spread="2.42"/>
                    <measurement group_id="O3" value="1.0" spread="2.43"/>
                    <measurement group_id="O4" value="1.5" spread="2.56"/>
                    <measurement group_id="O5" value="1.7" spread="2.32"/>
                    <measurement group_id="O6" value="1.4" spread="1.82"/>
                    <measurement group_id="O7" value="1.3" spread="2.25"/>
                    <measurement group_id="O8" value="2.0" spread="2.59"/>
                    <measurement group_id="O9" value="1.3" spread="2.28"/>
                    <measurement group_id="O10" value="1.8" spread="2.11"/>
                    <measurement group_id="O11" value="1.6" spread="1.90"/>
                    <measurement group_id="O12" value="2.2" spread="2.70"/>
                    <measurement group_id="O13" value="1.9" spread="2.62"/>
                    <measurement group_id="O14" value="1.4" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</title>
        <description>GMFR of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</title>
          <description>GMFR of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.17"/>
                    <measurement group_id="O2" value="1.0" spread="1.18"/>
                    <measurement group_id="O3" value="0.9" spread="1.12"/>
                    <measurement group_id="O4" value="1.0" spread="1.22"/>
                    <measurement group_id="O5" value="1.0" spread="1.11"/>
                    <measurement group_id="O6" value="0.9" spread="1.22"/>
                    <measurement group_id="O7" value="0.9" spread="1.18"/>
                    <measurement group_id="O8" value="1.0" spread="1.67"/>
                    <measurement group_id="O9" value="0.9" spread="1.98"/>
                    <measurement group_id="O10" value="1.0" spread="1.12"/>
                    <measurement group_id="O11" value="1.0" spread="1.13"/>
                    <measurement group_id="O12" value="7.4" spread="2.97"/>
                    <measurement group_id="O13" value="4.5" spread="2.94"/>
                    <measurement group_id="O14" value="5.7" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.91"/>
                    <measurement group_id="O2" value="5.1" spread="2.78"/>
                    <measurement group_id="O3" value="1.7" spread="1.81"/>
                    <measurement group_id="O4" value="2.6" spread="2.78"/>
                    <measurement group_id="O5" value="4.2" spread="3.20"/>
                    <measurement group_id="O6" value="3.7" spread="3.17"/>
                    <measurement group_id="O7" value="1.6" spread="2.06"/>
                    <measurement group_id="O8" value="5.9" spread="4.17"/>
                    <measurement group_id="O9" value="2.7" spread="3.16"/>
                    <measurement group_id="O10" value="4.6" spread="2.73"/>
                    <measurement group_id="O11" value="3.1" spread="2.36"/>
                    <measurement group_id="O12" value="4.6" spread="2.94"/>
                    <measurement group_id="O13" value="3.6" spread="2.62"/>
                    <measurement group_id="O14" value="4.0" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="1.8" spread="2.34"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="2.4" spread="2.89"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="1.4" spread="2.08"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="1.9" spread="2.56"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</title>
        <description>GMFR of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Antibody Titers of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</title>
          <description>GMFR of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.22"/>
                    <measurement group_id="O2" value="1.0" spread="1.26"/>
                    <measurement group_id="O3" value="0.9" spread="1.12"/>
                    <measurement group_id="O4" value="1.0" spread="1.18"/>
                    <measurement group_id="O5" value="0.9" spread="1.22"/>
                    <measurement group_id="O6" value="1.0" spread="1.09"/>
                    <measurement group_id="O7" value="0.9" spread="1.47"/>
                    <measurement group_id="O8" value="1.1" spread="1.91"/>
                    <measurement group_id="O9" value="1.0" spread="1.05"/>
                    <measurement group_id="O10" value="1.0" spread="1.25"/>
                    <measurement group_id="O11" value="1.0" spread="1.06"/>
                    <measurement group_id="O12" value="2.2" spread="2.48"/>
                    <measurement group_id="O13" value="2.5" spread="2.80"/>
                    <measurement group_id="O14" value="2.8" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.59"/>
                    <measurement group_id="O2" value="2.3" spread="2.10"/>
                    <measurement group_id="O3" value="1.3" spread="1.67"/>
                    <measurement group_id="O4" value="1.3" spread="1.48"/>
                    <measurement group_id="O5" value="2.0" spread="2.46"/>
                    <measurement group_id="O6" value="1.7" spread="1.82"/>
                    <measurement group_id="O7" value="1.1" spread="1.60"/>
                    <measurement group_id="O8" value="2.9" spread="3.50"/>
                    <measurement group_id="O9" value="1.6" spread="1.77"/>
                    <measurement group_id="O10" value="2.5" spread="2.62"/>
                    <measurement group_id="O11" value="2.0" spread="2.02"/>
                    <measurement group_id="O12" value="1.8" spread="2.25"/>
                    <measurement group_id="O13" value="1.9" spread="2.30"/>
                    <measurement group_id="O14" value="2.1" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="1.4" spread="1.93"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="1.6" spread="2.10"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="1.0" spread="1.78"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="1.4" spread="2.28"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Antibody Titers of Strains Not Represented in the Investigational Vaccine: Cross-Protection Assays</title>
        <description>GMFR of anti-norovirus Cross-Protection Assays: GII.2 EC50, GI.3 EC50 and GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
        <time_frame>Day 56</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Antibody Titers of Strains Not Represented in the Investigational Vaccine: Cross-Protection Assays</title>
          <description>GMFR of anti-norovirus Cross-Protection Assays: GII.2 EC50, GI.3 EC50 and GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GII.2 EC50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.92"/>
                    <measurement group_id="O2" value="0.8" spread="3.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI.3 EC50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="3.23"/>
                    <measurement group_id="O2" value="3.0" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GII.4.2012 EC50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.50"/>
                    <measurement group_id="O2" value="4.1" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Cincinnati (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus GII.4 Cincinnati antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.7" spread="4.34"/>
                    <measurement group_id="O2" value="75.1" spread="3.85"/>
                    <measurement group_id="O3" value="114.7" spread="4.28"/>
                    <measurement group_id="O4" value="85.8" spread="4.19"/>
                    <measurement group_id="O5" value="63.0" spread="4.08"/>
                    <measurement group_id="O6" value="89.1" spread="4.13"/>
                    <measurement group_id="O7" value="99.8" spread="4.47"/>
                    <measurement group_id="O8" value="85.0" spread="4.64"/>
                    <measurement group_id="O9" value="91.8" spread="4.02"/>
                    <measurement group_id="O10" value="112.6" spread="3.26"/>
                    <measurement group_id="O11" value="134.8" spread="3.07"/>
                    <measurement group_id="O12" value="54.0" spread="3.95"/>
                    <measurement group_id="O13" value="81.8" spread="3.86"/>
                    <measurement group_id="O14" value="93.2" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" spread="4.31"/>
                    <measurement group_id="O2" value="72.9" spread="3.95"/>
                    <measurement group_id="O3" value="113.8" spread="4.02"/>
                    <measurement group_id="O4" value="83.3" spread="4.05"/>
                    <measurement group_id="O5" value="61.7" spread="4.04"/>
                    <measurement group_id="O6" value="84.4" spread="4.23"/>
                    <measurement group_id="O7" value="90.5" spread="4.16"/>
                    <measurement group_id="O8" value="88.0" spread="5.49"/>
                    <measurement group_id="O9" value="78.6" spread="4.06"/>
                    <measurement group_id="O10" value="109.0" spread="3.25"/>
                    <measurement group_id="O11" value="130.6" spread="2.95"/>
                    <measurement group_id="O12" value="400.0" spread="3.57"/>
                    <measurement group_id="O13" value="366.9" spread="4.60"/>
                    <measurement group_id="O14" value="534.2" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.3" spread="3.57"/>
                    <measurement group_id="O2" value="380.7" spread="3.61"/>
                    <measurement group_id="O3" value="200.3" spread="4.33"/>
                    <measurement group_id="O4" value="221.0" spread="3.66"/>
                    <measurement group_id="O5" value="263.7" spread="5.77"/>
                    <measurement group_id="O6" value="327.5" spread="4.12"/>
                    <measurement group_id="O7" value="161.5" spread="4.66"/>
                    <measurement group_id="O8" value="501.4" spread="5.07"/>
                    <measurement group_id="O9" value="248.5" spread="4.56"/>
                    <measurement group_id="O10" value="518.8" spread="3.40"/>
                    <measurement group_id="O11" value="415.5" spread="4.11"/>
                    <measurement group_id="O12" value="248.3" spread="4.01"/>
                    <measurement group_id="O13" value="296.5" spread="4.12"/>
                    <measurement group_id="O14" value="373.4" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="113.5" spread="5.03"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="202.5" spread="4.06"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="88.9" spread="3.90"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="160.8" spread="3.96"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</title>
        <description>Blocking Titers 50 (BT50) of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Days 28, 56, 208 and 393</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: GII.4 Sydney (HBGA)</title>
          <description>Blocking Titers 50 (BT50) of anti-norovirus GII.4 Sydney antibody titers as measured by HBGA binding assay.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. &quot;n&quot; in the category is the number of participants with data available at the given time-point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="28"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="24"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>D1 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0" spread="3.86"/>
                    <measurement group_id="O2" value="26.0" spread="2.30"/>
                    <measurement group_id="O3" value="43.3" spread="3.29"/>
                    <measurement group_id="O4" value="32.4" spread="3.24"/>
                    <measurement group_id="O5" value="28.3" spread="2.45"/>
                    <measurement group_id="O6" value="37.5" spread="3.18"/>
                    <measurement group_id="O7" value="29.7" spread="3.34"/>
                    <measurement group_id="O8" value="28.0" spread="2.93"/>
                    <measurement group_id="O9" value="32.2" spread="3.09"/>
                    <measurement group_id="O10" value="28.1" spread="2.31"/>
                    <measurement group_id="O11" value="32.3" spread="2.79"/>
                    <measurement group_id="O12" value="21.6" spread="2.11"/>
                    <measurement group_id="O13" value="29.7" spread="2.48"/>
                    <measurement group_id="O14" value="37.3" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D28 (n=30,29,27,29,30,31,30,32,27,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6" spread="3.49"/>
                    <measurement group_id="O2" value="24.8" spread="2.29"/>
                    <measurement group_id="O3" value="42.5" spread="3.10"/>
                    <measurement group_id="O4" value="31.1" spread="3.12"/>
                    <measurement group_id="O5" value="26.4" spread="2.44"/>
                    <measurement group_id="O6" value="36.3" spread="3.09"/>
                    <measurement group_id="O7" value="25.9" spread="3.08"/>
                    <measurement group_id="O8" value="30.2" spread="3.87"/>
                    <measurement group_id="O9" value="32.9" spread="3.09"/>
                    <measurement group_id="O10" value="27.8" spread="2.28"/>
                    <measurement group_id="O11" value="31.8" spread="2.73"/>
                    <measurement group_id="O12" value="48.0" spread="3.37"/>
                    <measurement group_id="O13" value="75.1" spread="3.35"/>
                    <measurement group_id="O14" value="104.8" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D56 (n=30,29,28,29,30,31,30,32,28,30,24,28,29,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" spread="3.93"/>
                    <measurement group_id="O2" value="59.3" spread="2.79"/>
                    <measurement group_id="O3" value="56.7" spread="3.06"/>
                    <measurement group_id="O4" value="40.6" spread="3.37"/>
                    <measurement group_id="O5" value="55.5" spread="3.33"/>
                    <measurement group_id="O6" value="62.1" spread="3.26"/>
                    <measurement group_id="O7" value="31.2" spread="3.04"/>
                    <measurement group_id="O8" value="80.6" spread="4.37"/>
                    <measurement group_id="O9" value="51.2" spread="3.31"/>
                    <measurement group_id="O10" value="70.4" spread="3.22"/>
                    <measurement group_id="O11" value="64.4" spread="3.52"/>
                    <measurement group_id="O12" value="38.8" spread="2.98"/>
                    <measurement group_id="O13" value="56.7" spread="3.15"/>
                    <measurement group_id="O14" value="79.1" spread="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D208 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="40.2" spread="3.14"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="44.2" spread="3.17"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D393 (n=0,0,0,0,30,0,0,32,0,0,0,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not collected</measurement>
                    <measurement group_id="O2" value="NA">Data not collected</measurement>
                    <measurement group_id="O3" value="NA">Data not collected</measurement>
                    <measurement group_id="O4" value="NA">Data not collected</measurement>
                    <measurement group_id="O5" value="28.5" spread="2.37"/>
                    <measurement group_id="O6" value="NA">Data not collected</measurement>
                    <measurement group_id="O7" value="NA">Data not collected</measurement>
                    <measurement group_id="O8" value="38.3" spread="2.87"/>
                    <measurement group_id="O9" value="NA">Data not collected</measurement>
                    <measurement group_id="O10" value="NA">Data not collected</measurement>
                    <measurement group_id="O11" value="NA">Data not collected</measurement>
                    <measurement group_id="O12" value="NA">Data not collected</measurement>
                    <measurement group_id="O13" value="NA">Data not collected</measurement>
                    <measurement group_id="O14" value="NA">Data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.2 EC50 (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.2 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Day 56</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.2 EC50 (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.2 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.2" spread="2.62"/>
                    <measurement group_id="O2" value="265.5" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295.8" spread="2.31"/>
                    <measurement group_id="O2" value="216.5" spread="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GI.3 EC50 (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GI.3 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Day 56</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GI.3 EC50 (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GI.3 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" spread="2.98"/>
                    <measurement group_id="O2" value="74.1" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="350.5" spread="3.05"/>
                    <measurement group_id="O2" value="222.7" spread="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.4.2012 EC50 (HBGA)</title>
        <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
        <time_frame>Day 1 (Baseline) and Day 56</time_frame>
        <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Blocking Titers 50 (BT50) of a Strain Not Represented in the Investigational Vaccine: Cross-Protection Assay: GII.4.2012 EC50 (HBGA)</title>
          <description>Blocking titers 50 (BT50) of anti-norovirus Cross-Protection Assay: GII.4.2012 EC50 antibody titers as measured by HBGA binding assay. Data was collected for selected arms only.
D=Day</description>
          <population>Per-Protocol Set included all participants who received both doses of trial vaccine and who had no major protocol violations. Data was only collected for 2 of the arms.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5" spread="4.07"/>
                    <measurement group_id="O2" value="50.7" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.6" spread="3.11"/>
                    <measurement group_id="O2" value="208.5" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Significant New Medical Conditions</title>
        <description>Significant new medical conditions will be evaluated by the investigator for the co-existence of any of the following conditions: Adverse events of special interest (AESIs) are predefined events for potential immune mediated disorders. All AESIs are medically evaluated to assess if they might indicate an immune-mediated disorder.
Immune mediated events (IMEs) are AEs that represent a new diagnosis of a chronic medical condition that was not present or suspected prior to enrollment.</description>
        <time_frame>Day 1 up to Day 56</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Significant New Medical Conditions</title>
          <description>Significant new medical conditions will be evaluated by the investigator for the co-existence of any of the following conditions: Adverse events of special interest (AESIs) are predefined events for potential immune mediated disorders. All AESIs are medically evaluated to assess if they might indicate an immune-mediated disorder.
Immune mediated events (IMEs) are AEs that represent a new diagnosis of a chronic medical condition that was not present or suspected prior to enrollment.</description>
          <population>Safety Analysis Set included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AESIs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="6.5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="6.3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="7.1"/>
                    <measurement group_id="O13" value="3.4"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IMEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</title>
        <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participants is unwilling to continue because of the AE.</description>
        <time_frame>Day 1 up to Day 56</time_frame>
        <population>Safety Analysis Set included all participants who received at least one dose of trial vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>GI.1/GII.4 (15/15) - MPL (50)</title>
            <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
          </group>
          <group group_id="O2">
            <title>GI.1/GII.4 (15/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O3">
            <title>GI.1/GII.4 (50/50) - MPL (50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O4">
            <title>GI.1/GII.4 (15/15) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O5">
            <title>GI.1/GII.4 (15/50) - MPL (15)</title>
            <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
          </group>
          <group group_id="O6">
            <title>GI.1/GII.4 (50/50) - MPL (15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O7">
            <title>GI.1/GII.4 (15/15)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O8">
            <title>GI.1/GII.4 (15/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O9">
            <title>GI.1/GII.4 (50/50)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O10">
            <title>GI.1/GII.4 (50/150)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O11">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
            <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
          </group>
          <group group_id="O12">
            <title>GI.1/GII.4 (15/50) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O13">
            <title>GI.1/GII.4 (50/150) x2</title>
            <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
          <group group_id="O14">
            <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
            <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event (AE) Leading to Withdrawal From the Study</title>
          <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination because continued participation imposes an unacceptable risk to the participant's health or the participants is unwilling to continue because of the AE.</description>
          <population>Safety Analysis Set included all participants who received at least one dose of trial vaccine.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="30"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="30"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="28"/>
                <count group_id="O13" value="29"/>
                <count group_id="O14" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited AEs 28 days after each vaccination (Day 1 to 56) and Serious Adverse Events (SAEs) throughout the trial (Up to Day 393)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>GI.1/GII.4 (15/15) - MPL (50)</title>
          <description>Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 Âµg of GI.1 norovirus virus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg monophosphoryl lipid A (MLP) and 500 Âµg aluminum hydroxide, IM on Day 28.</description>
        </group>
        <group group_id="E2">
          <title>GI.1/GII.4 (15/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E3">
          <title>GI.1/GII.4 (50/50) - MPL (50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 50 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E4">
          <title>GI.1/GII.4 (15/15) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E5">
          <title>GI.1/GII.4 (15/50) - MPL (15)</title>
          <description>IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, on Day 28.</description>
        </group>
        <group group_id="E6">
          <title>GI.1/GII.4 (50/50) - MPL (15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 15 Âµg MLP and 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E7">
          <title>GI.1/GII.4 (15/15)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 15 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E8">
          <title>GI.1/GII.4 (15/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E9">
          <title>GI.1/GII.4 (50/50)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E10">
          <title>GI.1/GII.4 (50/150)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E11">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167)</title>
          <description>Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 28.</description>
        </group>
        <group group_id="E12">
          <title>GI.1/GII.4 (15/50) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="E13">
          <title>GI.1/GII.4 (50/150) x2</title>
          <description>Norovirus bivalent VLP vaccine (50 Âµg of GI.1 norovirus VLP and 150 Âµg GII.4 norovirus VLP) adjuvanted with 500 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
        <group group_id="E14">
          <title>GI.1/GII.4 (15/50) - Al(OH)3 (167) x2</title>
          <description>Norovirus bivalent VLP vaccine (15 Âµg of GI.1 norovirus VLP and 50 Âµg GII.4 norovirus VLP) adjuvanted with 167 Âµg aluminum hydroxide, IM, on Day 1 and Day 28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Large intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Leptospirosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

